<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">40499</article-id><article-id pub-id-type="doi">10.7554/eLife.40499</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Quantitative mapping of protein-peptide affinity landscapes using spectrally encoded beads</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-120177"><name><surname>Nguyen</surname><given-names>Huy Quoc</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5252-0062</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-120179"><name><surname>Roy</surname><given-names>Jagoree</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-120178"><name><surname>Harink</surname><given-names>Björn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-120180"><name><surname>Damle</surname><given-names>Nikhil P</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa2">§</xref></contrib><contrib contrib-type="author" id="author-138634"><name><surname>Latorraca</surname><given-names>Naomi R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-120181"><name><surname>Baxter</surname><given-names>Brian C</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-120182"><name><surname>Brower</surname><given-names>Kara</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-138633"><name><surname>Longwell</surname><given-names>Scott A</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15347"><name><surname>Kortemme</surname><given-names>Tanja</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-88363"><name><surname>Thorn</surname><given-names>Kurt S</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa3">#</xref></contrib><contrib contrib-type="author" id="author-15166"><name><surname>Cyert</surname><given-names>Martha S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3825-7437</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-104817"><name><surname>Fordyce</surname><given-names>Polly Morrell</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9505-0638</contrib-id><email>pfordyce@stanford.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Genetics</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Biology</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Biophysics Program</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Biochemistry and Biophysics</institution><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Department of Bioengineering</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Department of Bioengineering and Therapeutic Sciences</institution><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Chan Zuckerberg Biohub</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">ChEM-H Institute</institution><institution>Stanford University</institution><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Marletta</surname><given-names>Michael A</given-names></name><role>Reviewing Editor</role><aff><institution>University of California, Berkeley</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Marletta</surname><given-names>Michael A</given-names></name><role>Senior Editor</role><aff><institution>University of California, Berkeley</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>‡</label><p>Genentech, South San Francisco, United States</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>OSTHUS GmbH, Eisenbahnweg, Aachen, Germany</p></fn><fn fn-type="present-address" id="pa3"><label>#</label><p>Zymergen, Inc, Emeryville, United States</p></fn><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>07</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e40499</elocation-id><history><date date-type="received" iso-8601-date="2018-08-08"><day>08</day><month>08</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2019-07-03"><day>03</day><month>07</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Nguyen et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Nguyen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-40499-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.40499.001</object-id><p>Transient, regulated binding of globular protein domains to Short Linear Motifs (SLiMs) in disordered regions of other proteins drives cellular signaling. Mapping the energy landscapes of these interactions is essential for deciphering and perturbing signaling networks but is challenging due to their weak affinities. We present a powerful technology (MRBLE-pep) that simultaneously quantifies protein binding to a library of peptides directly synthesized on beads containing unique spectral codes. Using MRBLE-pep, we systematically probe binding of calcineurin (CN), a conserved protein phosphatase essential for the immune response and target of immunosuppressants, to the PxIxIT SLiM. We discover that flanking residues and post-translational modifications critically contribute to PxIxIT-CN affinity and identify CN-binding peptides based on multiple scaffolds with a wide range of affinities. The quantitative biophysical data provided by this approach will improve computational modeling efforts, elucidate a broad range of weak protein-SLiM interactions, and revolutionize our understanding of signaling networks.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>microfluidics</kwd><kwd>spectral encoding</kwd><kwd>calcineurin</kwd><kwd>protein-peptide interactions</kwd><kwd>protein specificity</kwd><kwd>phophatase specificity</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>DP2GM123641</award-id><principal-award-recipient><name><surname>Fordyce</surname><given-names>Polly Morrell</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R01GM107132</award-id><principal-award-recipient><name><surname>Thorn</surname><given-names>Kurt S</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R01GM119336</award-id><principal-award-recipient><name><surname>Cyert</surname><given-names>Martha S</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R01GM117189</award-id><principal-award-recipient><name><surname>Kortemme</surname><given-names>Tanja</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R01GM110089</award-id><principal-award-recipient><name><surname>Kortemme</surname><given-names>Tanja</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Chan Zuckerberg Biohub</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kortemme</surname><given-names>Tanja</given-names></name><name><surname>Fordyce</surname><given-names>Polly Morrell</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000879</institution-id><institution>Alfred P. Sloan Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Fordyce</surname><given-names>Polly Morrell</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000997</institution-id><institution>Arnold and Mabel Beckman Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Fordyce</surname><given-names>Polly Morrell</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A novel high-throughput method for measuring many weak protein-peptide affinities simultaneously reveals how calcineurin, a human phosphatase essential for the immune response, recognizes its peptide substrates.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p><italic>In vivo</italic>, rapid regulation of weak, transient protein-protein interactions is essential for dynamically shaping cellular responses. Nearly 40% of these interactions are mediated by 3–10 amino acid Short Linear Motifs (SLiMs) interacting with protein globular domains (<italic>e.g.</italic> SH3, SH2, and PDZ domains) or enzymes (<italic>e.g.</italic> kinases and phosphatases) (<xref ref-type="bibr" rid="bib18">Dinkel et al., 2016</xref>; <xref ref-type="bibr" rid="bib61">Neduva and Russell, 2006</xref>; <xref ref-type="bibr" rid="bib78">Tompa et al., 2014</xref>). The human proteome is estimated to contain more than 100,000 of these SLiMs, many of which are highly regulated by post-translational modifications (PTMs) such as phosphorylation (<xref ref-type="bibr" rid="bib78">Tompa et al., 2014</xref>; <xref ref-type="bibr" rid="bib41">Ivarsson and Jemth, 2019</xref>). As the weak affinities of these interactions (<inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values of ∼1 to 500 μM) are often close to the physiological concentrations of the interacting partners <italic>in vivo</italic>, subtle differences in concentrations or interaction affinities can have large effects on the fraction bound and downstream signaling output (<xref ref-type="bibr" rid="bib68">Roy et al., 2007</xref>; <xref ref-type="bibr" rid="bib36">Hein et al., 2017</xref>). Measuring and predicting not only which SLiMs a protein binds but also the affinities of SLiM-binding interactions is therefore essential for predicting signal strengths within signaling networks, understanding how these networks are perturbed by human disease, and identifying new therapeutic inhibitors (<xref ref-type="bibr" rid="bib80">Uyar et al., 2014</xref>).</p><p>Calcineurin (CN), a conserved Ca<sup>2+</sup>/calmodulin-dependent phosphatase, is a prime example of a signaling protein that relies on weak SLiM-mediated interactions for substrate recognition. Although CN plays critical roles in the human immune, nervous, and cardiovascular systems and likely dephosphorylates hundreds of downstream targets, only ∼70 are known to date (<xref ref-type="bibr" rid="bib72">Sheftic et al., 2016</xref>). These include the NFAT family of transcription factors, whose dephosphorylation by CN is required for T-cell activation and adaptive immunity (<xref ref-type="bibr" rid="bib42">Jain et al., 1993</xref>). Consequently, CN is the target of the widely used immunosuppressants cyclosporin A (CysA) and FK506. CN dephosphorylates sites with little sequence similarity, instead recognizing substrates by binding to two characterized SLiMs (PxIxIT and LxVP) located at variable distances from the phosphosite (<xref ref-type="bibr" rid="bib69">Roy and Cyert, 2009</xref>). Blocking SLiM binding to CN prevents dephosphorylation without altering its catalytic center: FK506 and CysA prevent LxVP docking, the viral inhibitor A238L blocks PxIxIT and LxVP binding, and the high-affinity peptide inhibitor PVIVIT blocks PxIxIT binding (<xref ref-type="bibr" rid="bib32">Grigoriu et al., 2013</xref>; <xref ref-type="bibr" rid="bib3">Aramburu et al., 1999</xref>). The affinities of PxIxIT motifs determine biological output by specifying the Ca<sup>2+</sup> concentration-dependence of substrate dephosphorylation <italic>in vivo</italic> (<xref ref-type="bibr" rid="bib58">Müller et al., 2009</xref>; <xref ref-type="bibr" rid="bib68">Roy et al., 2007</xref>). However, the relationship between PxIxIT sequence and CN binding affinity has never been probed outside of the core motif. A comprehensive understanding of PxIxIT-CN binding would allow discovery of novel CN substrates and aid efforts to rationally design CN inhibitors with enhanced selectivity.</p><p>Unfortunately, the limited binding interfaces associated with SLiM-mediated interactions result in low to moderate affinities (with typical <inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values in the range of 1–500 uM), high dissociation rates (<xref ref-type="bibr" rid="bib84">Zhou, 2012</xref>; <xref ref-type="bibr" rid="bib19">Dogan et al., 2015</xref>), and a rapid equilibrium (<xref ref-type="bibr" rid="bib30">Gianni and Jemth, 2017</xref>; <xref ref-type="bibr" rid="bib5">Bagshaw, 2017</xref>), complicating experimental efforts to measure affinities. Display-based methods such as combinatorial phage display (<xref ref-type="bibr" rid="bib79">Tonikian et al., 2008</xref>) and ProP-PD (<xref ref-type="bibr" rid="bib40">Ivarsson et al., 2014</xref>; <xref ref-type="bibr" rid="bib75">Sundell and Ivarsson, 2014</xref>) allow screening for binding between a protein of interest and large libraries (up to 10<sup>10</sup>) of candidate SLiM-containing peptides. However, these methods typically identify only strong binders, cannot return negative information about residues that ablate binding critical for downstream target prediction in vivo (<xref ref-type="bibr" rid="bib29">Gfeller et al., 2011</xref>), and do not directly probe effects of PTMs. Array-based methods (<xref ref-type="bibr" rid="bib22">Fodor et al., 1991</xref>) allow quantification of binding of labeled proteins to 10s-100s (SPOT arrays) (<xref ref-type="bibr" rid="bib24">Frank et al., 1990</xref>), tens of thousands (<xref ref-type="bibr" rid="bib4">Atwater et al., 2018</xref>), or millions (ultra-high density arrays) (<xref ref-type="bibr" rid="bib9">Buus et al., 2012</xref>; <xref ref-type="bibr" rid="bib23">Forsström et al., 2014</xref>; <xref ref-type="bibr" rid="bib65">Price et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Carmona et al., 2015</xref>) of peptides chemically synthesized <italic>in situ</italic>, permitting direct incorporation of PTMs or unnatural amino acids at specific positions (<xref ref-type="bibr" rid="bib20">Engelmann et al., 2014</xref>; <xref ref-type="bibr" rid="bib77">Tinti et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">Filippakopoulos et al., 2012</xref>). However, it is difficult to evaluate the yield and purity of peptides in each spot, contributing to false positives and negatives (<xref ref-type="bibr" rid="bib77">Tinti et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">Blikstad and Ivarsson, 2015</xref>). Most importantly, display- and array-based screening methods cannot measure quantitative interaction affinities (<inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>s or <inline-formula><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>s), as these measurements require washes that take the system out of thermodynamic equilibrium and lead to preferential loss of interactions with faster off-rates (<xref ref-type="bibr" rid="bib84">Zhou, 2012</xref>; <xref ref-type="bibr" rid="bib19">Dogan et al., 2015</xref>; <xref ref-type="bibr" rid="bib41">Ivarsson and Jemth, 2019</xref>). As a result, candidate interactions identified through screening methods are typically validated and their affinities quantified via subsequent quantitative, low-throughput methods that require large amounts of material and are labor-intensive (<italic>e.g.</italic> isothermal calorimetry, fluorescence polarization, or surface plasmon resonance) (<xref ref-type="bibr" rid="bib31">Gibson et al., 2015</xref>; <xref ref-type="bibr" rid="bib16">Davey et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Dinkel et al., 2016</xref>; <xref ref-type="bibr" rid="bib79">Tonikian et al., 2008</xref>). The ability to measure binding affinities for hundreds of protein-peptide interactions in parallel would simultaneously remove this validation and quantification bottleneck and allow quantitative mapping of binding specificity landscapes to improve target prediction <italic>in vivo</italic>.</p><p>Here, we present a powerful bead-based technology for quantitatively measuring affinities for many SLiM-mediated protein-peptide interactions in parallel using very small amounts of material. Peptides are synthesized directly on spectrally encoded beads (MRBLEs, Microspheres with Ratiometric Barcode Lanthanide Encoding) (<xref ref-type="bibr" rid="bib28">Gerver et al., 2012</xref>; <xref ref-type="bibr" rid="bib62">Nguyen et al., 2017a</xref>) with a unique linkage between each peptide sequence and a given spectral code. MRBLE-pep libraries can then be pooled and assayed for protein binding in a single small volume before being imaged to identify the peptide sequence associated with each bead and quantify the amount of protein bound. On-MRBLE chemical synthesis allows for precise control of peptide density, incorporation of PTMs at known locations, and in-line assessment of peptide quality via mass spectrometry to identify amino acids that ablate and promote protein binding with equal confidence. Most importantly, MRBLE polymeric beads have been deliberately engineered to have slow on- and off-rates, thereby slowing dissociation and allowing quantitative measurement interaction strengths for of weak and transient interactions difficult to detect via other techniques. MRBLE-pep provides a critical complement to high-throughput screening approaches, enabling facile downstream screening of candidate motif hits as well as systematic mapping of how individual residues at each position within the motif contribute to binding affinity and specificity.</p><p>We use MRBLE-pep to systematically mutate residues at each position within and flanking three previously-characterized PxIxIT sequences and quantify their effects on affinity. We find that flanking amino acids and post-translational modifications play surprisingly critical and previously unappreciated roles in determining affinity and specificity. Through iterative cycles of mutagenesis, <italic>in vitro</italic> affinity measurements, and <italic>in vivo</italic> activity measurements, we map the CN-PxIxIT affinity landscape and identify several PxIxIT peptides of unprecedented binding affinity that could prove useful for future development of additional potent CN inhibitors. This approach can be applied to a broad range of protein-SLiM interactions to map binding energy landscapes, model signaling networks, and identify novel therapeutic inhibitors.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>MRBLE-pep experimental assay overview</title><p>We developed a new high-throughput protein-peptide interaction assay based on spectrally encoded hydrogel beads containing unique ratios of lanthanide nanophosphors (MRBLEs) (<xref ref-type="bibr" rid="bib28">Gerver et al., 2012</xref>; <xref ref-type="bibr" rid="bib62">Nguyen et al., 2017a</xref>). MRBLEs containing a given code are output to a filtered-tip in a 96-well format or two 48–2 mL reaction tubes (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). These tips or tubes are then transferred to a peptide synthesizer for functionalization and solid phase peptide synthesis (SPPS), thereby uniquely linking peptide sequences with spectral codes (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) (<xref ref-type="bibr" rid="bib37">Hintersteiner et al., 2009</xref>; <xref ref-type="bibr" rid="bib48">Lam et al., 1991</xref>; <xref ref-type="bibr" rid="bib50">Lee et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Liu et al., 2002</xref>; <xref ref-type="bibr" rid="bib56">Meldal, 2002</xref>). Following SPPS, MRBLE-bound peptide libraries are pooled, incubated with an epitope-tagged protein of interest and a fluorescently-labeled antibody, washed, and imaged to reveal the peptide sequence associated with each bead (by quantifying lanthanide emissions) and the amount of protein bound (by quantifying fluorescence) (<xref ref-type="fig" rid="fig1">Figure 1B,C</xref>). Unlike commercially available spectrally encoded beads (<italic>e.g</italic>. Luminex), spectral codes can be ‘read’ using a single UV excitation source, preserving the ability to multiplex binding measurements using up to three detection antibodies (<xref ref-type="bibr" rid="bib63">Nguyen et al., 2017b</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.40499.002</object-id><label>Figure 1.</label><caption><title>MRBLE-pep experimental pipeline for high-throughput measurement of protein-peptide interactions.</title><p>(<bold>A</bold>) Encoded beads are synthesized in a microfluidic device and output to peptide synthesis tips arrayed in a 96 well plate format with one MRBLE code per tip. Peptides are then synthesized directly on MRBLEs via solid phase peptide synthesis with a unique 1:1 linkage between peptide sequence and spectral code. (<bold>B</bold>) MRBLE-pep libraries are pooled and incubated with an epitope-tagged protein and fluorescently-labeled antibody. (<bold>C</bold>) Following incubation and washing, peptide sequence and amount of bound protein are determined via imaging. (<bold>D</bold>) Example data showing images of MRBLE-pep beads coated with a CN-bound and negative control peptide, measured lanthanide ratios, and bound antibody intensities.</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.40499.007</object-id><label>Figure 1—source data 1.</label><caption><title>PVIVIT code ratios.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig1-data1-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><object-id pub-id-type="doi">10.7554/eLife.40499.008</object-id><label>Figure 1—source data 2.</label><caption><title>‘PVIAVT code ratios.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig1-data2-v2.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Integrated peptide quality control and quantification.</title><p>(<bold>A</bold>) Synthesis scheme for functionalizing MRBLE cores with an acid-labile rink amide linker and MRBLE shells with an acid-resistant glycine linker (<xref ref-type="bibr" rid="bib54">Liu et al., 2002</xref>). (<bold>B</bold>) Experimental pipeline for peptide elution, quality control, and quantification.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.004</object-id><label>Figure 1—figure supplement 2.</label><caption><title>MRBLE spectral codes are unaffected by chemical reagents required for peptide synthesis.</title><p>Each embedded MRBLE code is composed of a unique combination of 4 lanthanides (Europium (Eu), Dysprosium (Dy), Samarium (Sm), and Thulium (Tm)) and expressed in terms of 3 ratios (Sm/Eu, Dy/Eu, and Tm/Eu). Histograms of Sm/Eu ratios within each bead remain unchanged after bead functionalization, rink amide coupling, peptide synthesis, and biotinylation (top). Scatter plots of Dy/Eu and Tm/Eu ratios for each of 5 possible Sm/Eu ratios demonstrate that these ratios also remain constant throughout the synthesis process (bottom).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.005</object-id><label>Figure 1—figure supplement 3.</label><caption><title>Streptavidin binding assay reveals any sequence-specific differences in peptide synthesis efficiency.</title><p>(<bold>A</bold>) Experimental pipeline for streptavidin binding assay. MRBLE peptide libraries are biotinylated, incubated with Alexa-647-labeled streptavidin, washed, and imaged to identify embedded spectral codes and peptide sequences associated with each bead as well as quantify the amount of bound streptavidin. (<bold>B</bold>) Example images showing Alexa-647-labeled streptavidin binding to biotinylated MRBLE libraries and image processing steps. (<bold>C</bold>) Histograms and scatter plots of MRBLE Sm/Eu, Dy/Eu, and Tm/Eu ratios showing 48 clearly resolved intensity clusters and resolvable spectral codes. (<bold>D</bold>) Measured bound streptavidin intensities (median ± standard error on the mean) for an example 48-code library containing multiple systematic variants of candidate calcineurin substrates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.006</object-id><label>Figure 1—figure supplement 4.</label><caption><title>Streptavidin binding assay can be used to determine peptide loading density.</title><p>Scatter plots of measured intensity per bead (median ± s.e.m) as a function of Alexa-647-labeled streptavidin concentration demonstrate that intensities saturate at approximately 20 nM labeled streptavidin. Each reaction includes ~7000 total beads in a 100 μL volume, suggesting that each individual bead displays ∼2 × 10<sup>8</sup> peptides.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig1-figsupp4-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Integrated synthesis quality control ensures production of full-length, correct peptide sequences</title><p>Computational prediction of novel CN-binding SLiMs <italic>in vivo</italic> can be improved by including information about residues that ablate binding (<xref ref-type="bibr" rid="bib46">Krystkowiak et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Kaushansky et al., 2010</xref>; <xref ref-type="bibr" rid="bib29">Gfeller et al., 2011</xref>). To accomplish this, we implemented in-line peptide quality assessment to ensure that any observed non-binding results from a true absence of interaction and not a failure to synthesize the correct peptide. MRBLEs were first functionalized with an acid-labile rink amide linker within the bead core and a non-labile glycine linker on the outer bead shell (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) (<xref ref-type="bibr" rid="bib55">Liu et al., 2011</xref>); varying the ratio of extendible to non-extendible glycine linkers in the bead shell allows tuning of displayed peptide density (<xref ref-type="bibr" rid="bib54">Liu et al., 2002</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2009</xref>). Next, peptides were synthesized on both linkers via standard Fmoc SPPS. Peptides coupled to the MRBLE core via the acid-labile linker were eluted during the final acid global deprotection step and can be verified via MALDI mass spectrometry. As peptides within the core are inaccessible to large proteins, elution allows sequence verification without reducing binding signal in downstream binding assays. Measured MRBLE lanthanide ratios before, during, and after SPPS remained constant, (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), establishing that embedded codes are unchanged by chemical exposures.</p><p>Measuring binding affinities from a single pooled assay requires reliable estimates of the effective concentration of each peptide, which could be skewed by sequence-dependent differences in SPPS efficiency. To detect any large differences, a portion of each MRBLE-pep library was biotinylated, incubated with labeled streptavidin (DyLight650-SA), washed, and imaged to quantify bound streptavidin. Bound DyLight650-SA intensities were relatively consistent between sequences (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>) and saturated at ∼20 nM DyLight650-SA for ∼7100 beads in a 100 μL reaction volume (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>), establishing a surface density of ∼2 × 10<sup>8</sup> peptide molecules per MRBLE.</p></sec><sec id="s2-3"><title>MRBLE-pep yields quantitative measurements of calcineurin binding affinities</title><p>Measuring CN-PxIxIT binding affinities represents a demanding test for a new protein-peptide interaction assay, as CN binds PxIxIT peptide with moderate-to-weak affinities (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) via surface interactions (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), and prior literature affinity estimates for a given substrate have varied over 50-fold (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, NFATc1 and RCAN1). To determine MRBLE-pep assay sensitivity and resolve discrepancies in prior measurements, we performed a pooled assay in which MRBLEs bearing 10 peptides (each synthesized on three spectral codes) were incubated with varying concentrations of His-tagged CN complexed with fluorescently-labeled anti-His antibody. These 10 peptides (the ‘Triplicate low’ dataset) represent all calcineurin-binding SLiMs for which affinities have been measured, including the known NFATc1, NFATc2, AKAP79, and RCAN1 natural CN-interacting PxIxIT binding sites (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) (<xref ref-type="bibr" rid="bib2">Aramburu et al., 1998</xref>; <xref ref-type="bibr" rid="bib32">Grigoriu et al., 2013</xref>; <xref ref-type="bibr" rid="bib52">Li et al., 2007</xref>; <xref ref-type="bibr" rid="bib57">Mulero et al., 2009</xref>), a set of 5 PVIVIT peptide mutants previously characterized via competitive fluorescence polarization assays (<xref ref-type="bibr" rid="bib3">Aramburu et al., 1999</xref>; <xref ref-type="bibr" rid="bib52">Li et al., 2007</xref>), and a scrambled negative control sequence. Consistent with previous observations, the high-affinity PVIVIT and PVIVVT variants showed strong binding, a scrambled peptide showed no binding, and the PVIAVT and PVIVIN variants showed low to intermediate binding (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>), with consistent results for the same peptide sequence synthesized on MRBLEs with different codes. NFATc2 and AKAP79 showed measurable binding and were therefore selected for further systematic mutagenesis. Although MALDI mass spectrometry confirmed successful synthesis of both RCAN1 and NFATc1 full-length peptides, binding was near the limit of detection in this assay (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.40499.009</object-id><label>Figure 2.</label><caption><title>MRBLEs allow quantitative measurement of CN-SLiM interactions in high-throughput.</title><p>(<bold>A</bold>) Sequence alignment for previously identified CN PxIxIT binding sites (see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> for references). (<bold>B</bold>) Crystal structure showing CN heterodimer bound to the A238L inhibitor including both PxIxIT and LxVP binding sites (PDB ID: 4F0Z). (<bold>C</bold>) Concentration-dependent binding for CN interacting with either PVIVIT variants (top), natural PxIxIT peptides (bottom), or a scrambled PxIxIT motif (bottom). Each peptide was synthesized on three different MRBLE codes (light grey lines); affinities were determined from global Langmuir isotherm fits (black) to median values at each concentration (grey circles). (<bold>D</bold>) MRBLE-derived and literature reported <inline-formula><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values for various CN-PxIxIT interactions. Grey solid line indicates linear regression between data sets; dotted line indicates expected 1:1 agreement. (<bold>E</bold>) Langmuir isotherm fits to concentration-dependent binding behavior for CN interacting with candidate high-affinity PVIVIT core variants.</p><p><supplementary-material id="fig2sdata1"><object-id pub-id-type="doi">10.7554/eLife.40499.013</object-id><label>Figure 2—source data 1.</label><caption><title>‘Triplicate low’ affinity measurements.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig2-data1-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><object-id pub-id-type="doi">10.7554/eLife.40499.014</object-id><label>Figure 2—source data 2.</label><caption><title>‘Triplicate high’ affinity measurements.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig2-data2-v2.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.010</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Time-dependent measurements of calcineurin binding demonstrating that calcineurin-MRBLE on-rates are slow.</title><p>Measured intensities (grey dots with interpolated line) for 6 PxIxIT variant peptides (PKIVIT, PSIVIT, PVIVIT, NFATc2, AVIVIT, and PAIVIT) as a function of time for a reaction concentration of 0.25 μM calcineurin. Intensities appear to saturate at 5–6 hr and decrease only slightly after 24 hr. Pink boxes signify the time window for all subsequent measurements.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.011</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Dissociation rate of calcineurin over a time period of 13–18 hr after reaching equilibrium.</title><p>Measured intensities for 3 PxIxIT variant peptides (PKIVIT, PVIVIT, and NFATc2) as a function of time for a reaction concentration of 2 µM calcineurin (top panel) and 62.5 nM (bottom panel). Bottom panel represent replicates of the same peptide sequences on two separate codes and are indicated by different colors (blue/red).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.012</object-id><label>Figure 2—figure supplement 3.</label><caption><title>'Triplicate high' library of reported PVIVIT and natural variants.</title><p>Amino acid letter in red text indicate the mutation from WT sequence (grey). Each peptide was synthesized separately onto three different codes (with the exception of HPVIVVTGPH with only two codes). Binding curves were fit with a Langmuir isotherm model to estimate binding affinity <italic><inline-formula><mml:math id="inf6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>.</italic></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig2-figsupp3-v2.tif"/></fig></fig-group><p>To determine binding affinities for each peptide, we globally fit all data from a given assay to a single-site binding model with the assumption that while individual <inline-formula><mml:math id="inf7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values may differ between peptides, the stoichiometry of binding remains constant (see Materials and methods). Although these measurements take place out of equilibrium due to the need to wash beads prior to imaging, we specifically engineered MRBLEs to have very slow on- and off-rates (with measured rates on the order of hours) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), allowing measured intensities to approximate equilibrium values to yield apparent dissociation constants (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Slow on- and off-rates have previously been observed for hydrogel particles and are known to scale with particle radius, as proteins initially encounter and bind bead-bound ligands and then slowly diffuse into the particle via iterative dissociation and rebinding events (<xref ref-type="bibr" rid="bib71">Shapiro et al., 2012</xref>). Resultant apparent <inline-formula><mml:math id="inf8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>s largely agree with previously published values (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) and establish that MRBLE-pep can resolve differences in weak affinities spanning from ∼0.20 to ∼50 μM (a dynamic range &gt; 2 orders of magnitude, comparable to SPR and FP; <xref ref-type="bibr" rid="bib43">Jiang and Barclay, 2009</xref>). MRBLE-pep apparent <italic><inline-formula><mml:math id="inf9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></italic>s slightly underestimate affinities relative to published values while preserving rank order and relative differences; therefore, we provide relative affinity differences (<inline-formula><mml:math id="inf10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>) in all subsequent analyses, which are unaffected by this shift.</p><p>Examination of known CN PxIxIT motifs (NFATc1, NFATc2) and a viral inhibitor (A238L) suggested a potential preference for positively charged (R, K) or hydroxyl (S) residues in the degenerate PxIxIT position 2 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). To evaluate assay reproducibility and whether these substitutions enhance binding, we measured binding to these same 10 peptides plus an additional 3 PVIVIT variants (PSIVIT, PRIVIT, PKIVIT) (‘triplicate high’) (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>). These data reproduce previously observed trends and additionally suggest that the PKIVIT peptide binds slightly more strongly than PVIVIT; therefore, we also selected PKIVIT for additional systematic mutagenesis.</p></sec><sec id="s2-4"><title>High-throughput MRBLE-pep mapping of the CN-PxIxIT binding energy landscape</title><p>Using this new assay, we experimentally mapped portions of the CN-PxIxIT binding energy landscape by measuring CN binding to two MRBLE-pep libraries for each of the PVIVIT, PKIVIT, NFATc2, and AKAP79 sequences containing systematic mutations in either the ‘core’ (positions 1–6) or ‘flanking’ PxIxIT residues (positions −1 and 7–9) (368 peptides total) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>, <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>, <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5</xref>, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref>, <xref ref-type="fig" rid="fig3s7">Figure 3—figure supplement 7</xref>, <xref ref-type="fig" rid="fig3s8">Figure 3—figure supplement 8</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>, <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>, <xref ref-type="supplementary-material" rid="fig3sdata4">Figure 3—source data 4</xref>, <xref ref-type="supplementary-material" rid="fig3sdata5">Figure 3—source data 5</xref>, <xref ref-type="supplementary-material" rid="fig3sdata6">Figure 3—source data 6</xref>, <xref ref-type="supplementary-material" rid="fig3sdata7">Figure 3—source data 7</xref>, <xref ref-type="supplementary-material" rid="fig3sdata8">Figure 3—source data 8</xref>). As the P and I residues in positions 1, 3, and 5 are known to be strongly conserved across substrates, we prioritized mutagenesis at other, less conserved positions. The optimal number of peptides to screen per assay depends on the competing effects of ligand depletion and competition, the fraction of peptides expected to bind, the range of interaction strengths, and the statistical robustness of each measurement (<xref ref-type="bibr" rid="bib64">Pollard, 2010</xref>). To reduce error and maximize the ability to resolve subtle differences, we profiled 48 peptides per reaction, with ∼100 beads per sequence in each assay. To ensure that measured binding resulted from a true CN-PxIxIT interaction and not nonspecific binding, we repeated all experiments at a single, high concentration (250 nM) using a CN N330A/I1331A/R332A mutant defective in PxIxIT binding (CN NIR) (<xref ref-type="bibr" rid="bib51">Li et al., 2004</xref>) and labeled antibody alone (<xref ref-type="fig" rid="fig3s9">Figure 3—figure supplement 9</xref>, <xref ref-type="fig" rid="fig3s10">Figure 3—figure supplement 10</xref>, <xref ref-type="fig" rid="fig3s11">Figure 3—figure supplement 11</xref>, <xref ref-type="fig" rid="fig3s12">Figure 3—figure supplement 12</xref>; <xref ref-type="supplementary-material" rid="fig3sdata9">Figure 3—source data 9</xref>, <xref ref-type="supplementary-material" rid="fig3sdata10">Figure 3—source data 10</xref>). Several peptides were strongly bound by anti-His antibody but did not show binding when the antibody was pre-incubated with His-tagged CN; peptides strongly bound by the CN NIR mutant (<italic>e.g.</italic> PRIRIT) were removed from downstream analysis. All PVIVIT, PKIVIT, and NFATc2 libraries and the AKAP79 ‘core’ mutation library were fit by a single-site binding model, permitting direct measurement of <inline-formula><mml:math id="inf11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> for each substitution. As measured intensities for the AKAP79 ‘flank’ mutation library never reached saturation, MRBLE-pep measurements provide only qualitative estimates of affinity effects.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.40499.015</object-id><label>Figure 3.</label><caption><title>MRBLE-pep mapping of the CN-PxIxIT binding energy landscape.</title><p>(<bold>A</bold>) Langmuir isotherm fits to concentration-dependent binding behavior for CN interacting with PVIVIT variants containing systematic mutations within position 2. (<bold>B</bold>) Relative change in binding affinity for individual substitutions at position 2 (as compared to WT). (<bold>C</bold>) Heat map showing relative affinities per substitution per position for 4 PxIxIT motifs. (<bold>D</bold>) Langmuir isotherm fits to concentration-dependent binding behavior for CN interacting with a medium-affinity PVIVIT variant containing the wild type histidine, a serine, and a phosphoserine at position 9. (<bold>E</bold>) Comparison of the effect on affinity for a particular substitution at a particular position in the PKIVIT motif (y axis) vs. the PVIVIT motif (x axis). Inset shows relative effects on affinity for various substitutions at the V4 position in PKIVIT (top) and PVIVIT (bottom), highlighting differential effects of an I substitution.</p><p><supplementary-material id="fig3sdata1"><object-id pub-id-type="doi">10.7554/eLife.40499.039</object-id><label>Figure 3—source data 1.</label><caption><title>Concentration-dependent binding data for PVIVIT core library.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig3-data1-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><object-id pub-id-type="doi">10.7554/eLife.40499.040</object-id><label>Figure 3—source data 2.</label><caption><title>Concentration-dependent binding data for PVIVIT flank library.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig3-data2-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><object-id pub-id-type="doi">10.7554/eLife.40499.041</object-id><label>Figure 3—source data 3.</label><caption><title>Concentration-dependent binding data for PKIVIT core library.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig3-data3-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><object-id pub-id-type="doi">10.7554/eLife.40499.042</object-id><label>Figure 3—source data 4.</label><caption><title>Concentration-dependent binding data for PKIVIT flank library.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig3-data4-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig3sdata5"><object-id pub-id-type="doi">10.7554/eLife.40499.043</object-id><label>Figure 3—source data 5.</label><caption><title>Concentration-dependent binding data for NFATc2 core library.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig3-data5-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig3sdata6"><object-id pub-id-type="doi">10.7554/eLife.40499.044</object-id><label>Figure 3—source data 6.</label><caption><title>Concentration-dependent binding data for NFATc2 flank library.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig3-data6-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig3sdata7"><object-id pub-id-type="doi">10.7554/eLife.40499.045</object-id><label>Figure 3—source data 7.</label><caption><title>Concentration-dependent binding data for AKAP79 core library.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig3-data7-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig3sdata8"><object-id pub-id-type="doi">10.7554/eLife.40499.046</object-id><label>Figure 3—source data 8.</label><caption><title>Concentration-dependent binding data for AKAP79 flank library.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig3-data8-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig3sdata9"><object-id pub-id-type="doi">10.7554/eLife.40499.047</object-id><label>Figure 3—source data 9.</label><caption><title>WT and mutant binding data for PVIVIT core library.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig3-data9-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig3sdata10"><object-id pub-id-type="doi">10.7554/eLife.40499.048</object-id><label>Figure 3—source data 10.</label><caption><title>WT and mutant binding data for PVIVIT, PKIVIT, NFACTc2, and AKAP79 core and flank libraries.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-40499-fig3-data10-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.016</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Concentration-dependent binding measurements for systematic mutations within the PVIVIT core motif.</title><p>For each sequence, measured change in binding affinity relative to the wild-type PVIVIT sequence was determined by a global fit to a single-site binding model (black line). The wild-type sequence is shown in italics and single amino acid substitutions are shown in red.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.017</object-id><label>Figure 3—figure supplement 2.</label><caption><title>Concentration-dependent binding measurements for systematic mutations flanking the PVIVIT motif.</title><p>For each sequence, measured change in binding affinity relative to the wild-type PVIVIT sequence was determined by a global fit to a single-site binding model (black line). The wild-type sequence is shown in italics and single amino acid substitutions are shown in red.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.018</object-id><label>Figure 3—figure supplement 3.</label><caption><title>Concentration-dependent binding measurements for systematic mutations within the PKIVIT core motif.</title><p>For each sequence, measured change in binding affinity relative to the wild-type PKIVIT sequence was determined by a global fit to a single-site binding model (black line). The wild-type sequence is shown in italics and single amino acid substitutions are shown in red.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.019</object-id><label>Figure 3—figure supplement 4.</label><caption><title>Concentration-dependent binding measurements for systematic mutations flanking the PKIVIT motif.</title><p>For each sequence, measured change in binding affinity relative to the wild-type PKIVIT sequence was determined by a global fit to a single-site binding model (black line). The wild-type sequence is shown in italics and single amino acid substitutions are shown in red.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp4-v2.tif"/></fig><fig id="fig3s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.020</object-id><label>Figure 3—figure supplement 5.</label><caption><title>Concentration-dependent binding measurements for systematic mutations within the NFATc2 core motif.</title><p>For each sequence, measured change in binding affinity relative to the wild-type PRIEIT sequence was determined by a global fit to a single-site binding model (black line). The wild-type sequence is shown in italics and single amino acid substitutions are shown in red.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp5-v2.tif"/></fig><fig id="fig3s6" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.021</object-id><label>Figure 3—figure supplement 6.</label><caption><title>Concentration-dependent binding measurements for systematic mutations flanking the NFATc2 motif.</title><p>For each sequence, measured change in binding affinity relative to the wild-type PRIEIT sequence was determined by a global fit to a single-site binding model (black line). The wild-type sequence is shown in italics and single amino acid substitutions are shown in red.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp6-v2.tif"/></fig><fig id="fig3s7" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.022</object-id><label>Figure 3—figure supplement 7.</label><caption><title>Concentration-dependent binding measurements for systematic mutations within the AKAP79 core motif.</title><p>For each sequence, measured change in binding affinity relative to the wild-type IAIIIT sequence was determined by a global fit to a single-site binding model (black line). The wild-type sequence is shown in italics and single amino acid substitutions are shown in red.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp7-v2.tif"/></fig><fig id="fig3s8" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.023</object-id><label>Figure 3—figure supplement 8.</label><caption><title>Concentration-dependent binding measurements for systematic mutations flanking the AKAP79 motif.</title><p>For each sequence, measured change in binding affinity relative to the wild-type IAIIIT sequence was determined by a global fit to a single-site binding model (black line); however, a lack of saturation precluded quantitative determination of changes in affinity. The wild-type sequence is shown in italics and single amino acid substitutions are shown in red.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp8-v2.tif"/></fig><fig id="fig3s9" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.024</object-id><label>Figure 3—figure supplement 9.</label><caption><title>Binding intensity comparisons for PVIVIT library.</title><p>Measured intensities for WT CN (blue), antibody alone (yellow), and a CN mutant defective in PxIxIT recognition (NIR, green) interacting with PVIVIT library peptides.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp9-v2.tif"/></fig><fig id="fig3s10" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.025</object-id><label>Figure 3—figure supplement 10.</label><caption><title>Binding intensity comparisons for PKIVIT library.</title><p>Measured intensities for WT CN (blue), antibody alone (yellow), and a CN mutant defective in PxIxIT recognition (NIR, green) interacting with PKIVIT library peptides.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp10-v2.tif"/></fig><fig id="fig3s11" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.026</object-id><label>Figure 3—figure supplement 11.</label><caption><title>Binding intensity comparisons for NFATc2 library.</title><p>Measured intensities for WT CN (blue), antibody alone (yellow), and a CN mutant defective in PxIxIT recognition (NIR, green) interacting with NFATc2 library peptides.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp11-v2.tif"/></fig><fig id="fig3s12" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.027</object-id><label>Figure 3—figure supplement 12.</label><caption><title>Binding intensity comparisons for AKAP79 library.</title><p>Measured intensities for WT CN (blue), antibody alone (yellow), and a CN mutant defective in PxIxIT recognition (NIR, green) interacting with AKAP79 library peptides.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp12-v2.tif"/></fig><fig id="fig3s13" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.028</object-id><label>Figure 3—figure supplement 13.</label><caption><title>Bar graphs showing PVIVIT specificity.</title><p>Relative affinity was calculated by normalizing all binding affinities (<inline-formula><mml:math id="inf12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>) to WT binding affinity (light blue: core, dark blue: flank). Phosphoserine and phosphothreonine are represented by 'X' and 'Z', respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp13-v2.tif"/></fig><fig id="fig3s14" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.029</object-id><label>Figure 3—figure supplement 14.</label><caption><title><inline-formula><mml:math id="inf13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> calculated in reference to PxIxIT WT (HPVIVITGPH).</title><p>Phosphoserine and phosphothreonine are represented by 'X' and 'Z', respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp14-v2.tif"/></fig><fig id="fig3s15" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.030</object-id><label>Figure 3—figure supplement 15.</label><caption><title>Relative affinity was calculated by normalizing all binding affinity (<inline-formula><mml:math id="inf14"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>) to WT binding affinity (light blue: core, dark blue: flank).</title><p>Peptide sequence AGPHPKIIITGPHEE (red) contains a PxIxIT motif similar to the A238L viral inhibitor.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp15-v2.tif"/></fig><fig id="fig3s16" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.031</object-id><label>Figure 3—figure supplement 16.</label><caption><title><inline-formula><mml:math id="inf15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> calculated in reference to PKIVIT WT.</title><p>Peptide sequence AGPHPKIIITGPHEE (red) contains a PxIxIT motif similar to the A238L viral inhibitor.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp16-v2.tif"/></fig><fig id="fig3s17" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.032</object-id><label>Figure 3—figure supplement 17.</label><caption><title>Relative affinity was calculated by normalizing all binding affinity (<inline-formula><mml:math id="inf16"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>) to WT (SPRIEITPSH) binding affinity (light blue: core, dark blue: flank).</title><p>Phosphoserine and phosphothreonine are represented by 'X' and 'Z', respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp17-v2.tif"/></fig><fig id="fig3s18" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.033</object-id><label>Figure 3—figure supplement 18.</label><caption><title><inline-formula><mml:math id="inf17"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> calculated in reference to WT peptide (SPRIEITPSH).</title><p>Phosphoserine and phosphothreonine are represented by 'X' and 'Z', respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp18-v2.tif"/></fig><fig id="fig3s19" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.034</object-id><label>Figure 3—figure supplement 19.</label><caption><title>Relative affinity was calculated by normalizing to peptides KRMEPIAIIITDTEIS.</title><p>Peptide sequence KRMEPKIIITTDTEIS (red) contains a PxIxIT motif equivalent to the A238L viral inhibitor. Phosphoserine and phosphothreonine are represented by 'X' and 'Z' respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp19-v2.tif"/></fig><fig id="fig3s20" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.035</object-id><label>Figure 3—figure supplement 20.</label><caption><title><inline-formula><mml:math id="inf18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> calculated in reference to peptide KRMEPIAIIITDTEIS.</title><p>Peptide sequence KRMEPKIIITTDTEIS (red) contains a PxIxIT motif equivalent to the A238L viral inhibitor. Phosphoserine and phosphothreonine are represented by 'X' and 'Z', respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp20-v2.tif"/></fig><fig id="fig3s21" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.036</object-id><label>Figure 3—figure supplement 21.</label><caption><title>Visualization of Log <italic><inline-formula><mml:math id="inf19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></italic> normalized to corresponding WT sequences.</title><p>Amino acid substitutions (single letter code) for all four scaffolds: PVIVIT, PKIVIT, NFATc2, and AKAP79. Positions P-1 to P9 are separated by columns and columns highlighted in yellow represents conserved positions from PxIxIT binding motif. Letters in large black-outlined text corresponds to the WT sequence for that scaffold. Red dotted line is relative affinity = 1. Phosphoserine and phosphothreonine are represented by 'X' and 'Z', respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp21-v2.tif"/></fig><fig id="fig3s22" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.037</object-id><label>Figure 3—figure supplement 22.</label><caption><title>LogoMaker logos for binding data.</title><p>Top: binding preferences for AKAP79 (left), NFATc2 (middle left), PKIVIT (middle right), and PVIVIT (right) represented as logos. Scale bar indicates a change in binding affinity of 1 kcal/mol; amino acids are arranged top-to-bottom in order of binding preference. Wild-type residues are shown in red; other residues are shown in grey. Bottom: Logos display residues not tested experimentally at each position to illustrate missing data.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp22-v2.tif"/></fig><fig id="fig3s23" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.038</object-id><label>Figure 3—figure supplement 23.</label><caption><title>Measured changes in binding affinity for mutations in PVIVIT (top panel) and PKIVIT (bottom panel) relative to the same mutations in the NFATc2 (PRIEIT) library.</title><p>Amino acid substitutions are colored according to hydrophobicity with the position of the substitution indicated.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig3-figsupp23-v2.tif"/></fig></fig-group><p>To visualize the binding affinity landscape of CN-PxIxIT interactions, we generated graphs showing the relative change in affinity upon substitution to each mutant amino acid at each position (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s13">Figure 3—figure supplement 13</xref>, <xref ref-type="fig" rid="fig3s14">Figure 3—figure supplement 14</xref>, <xref ref-type="fig" rid="fig3s15">Figure 3—figure supplement 15</xref>, <xref ref-type="fig" rid="fig3s16">Figure 3—figure supplement 16</xref>, <xref ref-type="fig" rid="fig3s17">Figure 3—figure supplement 17</xref>, <xref ref-type="fig" rid="fig3s18">Figure 3—figure supplement 18</xref>, <xref ref-type="fig" rid="fig3s19">Figure 3—figure supplement 19</xref>, <xref ref-type="fig" rid="fig3s20">Figure 3—figure supplement 20</xref>, <xref ref-type="fig" rid="fig3s21">Figure 3—figure supplement 21</xref>); information at all positions can be combined to produce a heat map of relative changes in binding energies (<inline-formula><mml:math id="inf20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>) (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) or scaled logos (<xref ref-type="fig" rid="fig3s22">Figure 3—figure supplement 22</xref>) (<xref ref-type="bibr" rid="bib76">Tareen and Kinney, 2019</xref>). Although considered to be degenerate in the consensus motif, many substitutions at positions 2 and 4 had unexpectedly strong effects on binding (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). In particular, V2R and V2K mutations in the PVIVIT scaffold significantly enhanced binding in experimental assays, consistent with previous observations of high-affinity CN binding to the viral inhibitor (A238L) containing a positively-charged residue at this position (PKIIIT) (<xref ref-type="bibr" rid="bib32">Grigoriu et al., 2013</xref>).</p></sec><sec id="s2-5"><title>Flanking residues play a major role in defining binding affinity and specificity</title><p>The experimental impact of sequences flanking the core ‘PxIxIT’ residues on CN binding has never been probed systematically. At the −1 position, MRBLE-pep data revealed a clear CN preference for hydrophobic residues (V,L,I) and a weak preference for polar residues (T, Y, H, N, and R) for all three of the PVIVIT, PKIVIT, and NFATc2 scaffolds. By contrast, substitution to acidic (D, E) residues at this position strongly reduced binding (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>, <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>, <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5</xref>, <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref>, <xref ref-type="fig" rid="fig3s13">Figure 3—figure supplement 13</xref>, <xref ref-type="fig" rid="fig3s14">Figure 3—figure supplement 14</xref>, <xref ref-type="fig" rid="fig3s15">Figure 3—figure supplement 15</xref>, <xref ref-type="fig" rid="fig3s16">Figure 3—figure supplement 16</xref>, <xref ref-type="fig" rid="fig3s17">Figure 3—figure supplement 17</xref>, <xref ref-type="fig" rid="fig3s18">Figure 3—figure supplement 18</xref>). At position 9, the majority of mutations in the PVIVIT scaffold increased affinity. Substitution of phosphomimetic residues (D, E) or unphosphorylated serine increased affinity slightly and not at all, respectively, but substitution of phosphoserine and phosphothreonine residues (X, Z) increased affinity nearly 50-fold (from <inline-formula><mml:math id="inf21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> = 170 + /- 40 nM to <inline-formula><mml:math id="inf22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> = 3.4 + /- 0.2 nM) (<xref ref-type="fig" rid="fig3">Figure 3C–D</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). This effect was specific to the PVIVIT sequence, with significantly less drastic increases and decreases in affinity observed for the same substitutions in the NFATc2 and AKAP79 scaffolds, respectively (<xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref>, <xref ref-type="fig" rid="fig3s8">Figure 3—figure supplement 8</xref>, <xref ref-type="fig" rid="fig3s23">Figure 3—figure supplement 23</xref>). These MRBLE-pep data establish that flanking residues make major contributions to affinity and the PxIxIT SLiM is significantly longer than previously thought.</p></sec><sec id="s2-6"><title>Effects of individual substitutions show evidence of non-additivity</title><p>Understanding the degree to which CN-SLiM binding specificity can be explained by a linear additive model is critical for estimating the likely accuracy of downstream efforts to identify substrates or design therapeutics. Deviations from additivity can be quantified via double-mutant cycle (DMC) analysis, in which the effects of individual mutations are measured alone and in combination and then compared. DMC analysis between the PVIVIT and PKIVIT scaffolds revealed that the V4F substitution resulted in a significant loss of affinity within the PVIVIT context but had only minor effects on PKIVIT binding; by contrast, V4I mutation of this solvent-exposed position significantly increased binding only within the PKIVIT sequence (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s23">Figure 3—figure supplement 23</xref>). This last substitution suggests that the high affinity of the PKIIIT sequence in the A238L inhibitor in particular relies on cooperativity between the position 2 and 4 residues. The magnitude of <inline-formula><mml:math id="inf23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> effects for the same substitution at the same position varies significantly between different backbones, further illustrating the importance of epistatic interactions in dictating overall binding strength. Although critical for improved prediction of <italic>in vivo</italic> substrates and outputs, these epistatic interactions are obscured in typical high-throughput screens and can only be observed in systematic pairwise measurements like those presented here.</p></sec><sec id="s2-7"><title>Comparing experimental measurements with results from structure-based computational predictions</title><p>To test the degree to which computational methods can quantitatively predict effects of amino acid substitutions within SLiMs on protein-SLiM binding affinities, we leveraged high-resolution co-crystal structures and recently-developed computational modeling techniques (<xref ref-type="bibr" rid="bib73">Smith and Kortemme, 2010</xref>; <xref ref-type="bibr" rid="bib6">Barlow et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Guerois et al., 2002</xref>; <xref ref-type="bibr" rid="bib70">Schymkowitz et al., 2005</xref>) to estimate the effects of each mutation. Co-crystal structures of CN bound to PVIVIT (PDB: 2P6B) (<xref ref-type="bibr" rid="bib52">Li et al., 2007</xref>) and AKAP79-derived PIAIIIT (PDB: 3LL8) (<xref ref-type="bibr" rid="bib53">Li et al., 2012</xref>) reveal that the conserved P1, I3, and I5 residues are buried in hydrophobic pockets on the CN surface in all three structures; for AKAP79, an I1 residue occupies the pocket typically occupied by a P1 residue. In both structures, the less-conserved solvent-exposed (positions 2 and 4) and flanking (positions −1 and 7–9) residues adopt variable side chain orientations (<xref ref-type="fig" rid="fig4">Figure 4A</xref>).</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.40499.049</object-id><label>Figure 4.</label><caption><title>Structure-based modeling predictions.</title><p>(<bold>A</bold>) Co-crystal structures showing zoomed in overlay of substrates (PDB: 2P6B). (<bold>B</bold>) Heat maps showing predicted changes in binding energy from the Rosetta ‘flex_ddG’ protocol for each amino acid substitution at each position for PVIVIT and IAIIIT targets. (<bold>C</bold>) Heat maps showing FoldX-predicted changes in binding energy for each amino acid substitution at each position for PVIVIT and IAIIIT targets. (<bold>D</bold>) Fraction of residues correctly predicted to be stabilizing or destabilizing by both models as a function of position for PVIVIT (top) and IAIIIT (bottom).</p><p><supplementary-material id="fig4sdata1"><object-id pub-id-type="doi">10.7554/eLife.40499.057</object-id><label>Figure 4—source data 1.</label><caption><title>Rosetta sequence tolerance protocol frequencies for PVIVIT.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig4-data1-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><object-id pub-id-type="doi">10.7554/eLife.40499.058</object-id><label>Figure 4—source data 2.</label><caption><title>Rosetta sequence tolerance protocol frequencies for IAIIIT.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig4-data2-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><object-id pub-id-type="doi">10.7554/eLife.40499.059</object-id><label>Figure 4—source data 3.</label><caption><title>Flex ddG-predicted <inline-formula><mml:math id="inf24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> values for PVIVIT.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig4-data3-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><object-id pub-id-type="doi">10.7554/eLife.40499.060</object-id><label>Figure 4—source data 4.</label><caption><title>Flex ddG-predicted <inline-formula><mml:math id="inf25"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> values for IAIIIT.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig4-data4-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><object-id pub-id-type="doi">10.7554/eLife.40499.061</object-id><label>Figure 4—source data 5.</label><caption><title>FoldX ddG-predicted <inline-formula><mml:math id="inf26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> values for PVIVIT.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig4-data5-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><object-id pub-id-type="doi">10.7554/eLife.40499.062</object-id><label>Figure 4—source data 6.</label><caption><title>FoldX ddG-predicted <inline-formula><mml:math id="inf27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> values for IAIIIT.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig4-data6-v2.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.050</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Rosetta Sequence Tolerance protocol frequencies.</title><p>Heat maps showing the frequencies with which each amino acid substitution is returned as most favorable by the Rosetta Sequence Tolerance protocol at each position for PVIVIT and IAIIIT targets.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.051</object-id><label>Figure 4—figure supplement 2.</label><caption><title>FoldX versus Rosetta predictions for PVIVIT.</title><p>Scatter plots comparing FoldX and Rosetta predictions for each position within the PVIVIT peptide.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.052</object-id><label>Figure 4—figure supplement 3.</label><caption><title>FoldX versus Rosetta predictions for IAIIIT.</title><p>Scatter plots comparing FoldX and Rosetta predictions for each position within the IAIIIT peptide.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.053</object-id><label>Figure 4—figure supplement 4.</label><caption><title>Measured affinities versus predicted amino acid frequencies.</title><p>Correlation between measured relative affinity and Backrub-predicted amino acid frequency for each substitution as a function of position. Residues are colored by biochemical properties (red = acidic, blue = basic, black = hydrophobic, green = all other residues).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig4-figsupp4-v2.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.054</object-id><label>Figure 4—figure supplement 5.</label><caption><title>Measured versus Rosetta-predicted changes in Gibbs free energies.</title><p>Correlation between measured and flex_ddG-predicted change in Gibbs free energy for each mutation at each position within PVIVIT and AKAP79 peptides. Each panel includes calculated correlation coefficients between MRBLE-pep measured changes in binding affinity (y axis) and Rosetta-predicted changes in binding affinity (x axis). Residues are colored by biochemical properties (red = acidic, blue = basic, black = hydrophobic, green = all other residues).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig4-figsupp5-v2.tif"/></fig><fig id="fig4s6" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.055</object-id><label>Figure 4—figure supplement 6.</label><caption><title>Measured versus FoldX-predicted changes in Gibbs free energies.</title><p>Correlation between measured and FoldX-predicted change in Gibbs free energy for each mutation at each position within PVIVIT and AKAP79 peptides. Each panel includes calculated correlation coefficients between MRBLE-pep measured changes in binding affinity (y axis) and FoldX-predicted changes in binding affinity (x axis). Residues are colored by biochemical properties (red = acidic, blue = basic, black = hydrophobic, green = all other residues).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig4-figsupp6-v2.tif"/></fig><fig id="fig4s7" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.056</object-id><label>Figure 4—figure supplement 7.</label><caption><title>MRBLE-pep measurements, FoldX predictions, and Rosetta predictions versus orthogonal affinity measurements for 3 PVIVIT variants.</title><p>Comparison between MRBLE-pep measurements (green), FoldX predictions (blue), and Rosetta predictions (red) versus previous literature measurements for the energetic effects of PVIVIN and PVIVVT single-site substitutions from the WT PVIVIT peptide. Literature <inline-formula><mml:math id="inf28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> values are calculated from <xref ref-type="bibr" rid="bib52">Li et al. (2007)</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig4-figsupp7-v2.tif"/></fig></fig-group><p>To predict mutational effects, we used computational methods implemented in the protein structure prediction and design programs Rosetta (<xref ref-type="bibr" rid="bib49">Leaver-Fay et al., 2011</xref>) and FoldX (<xref ref-type="bibr" rid="bib33">Guerois et al., 2002</xref>; <xref ref-type="bibr" rid="bib70">Schymkowitz et al., 2005</xref>). The Rosetta Sequence Tolerance protocol (<xref ref-type="bibr" rid="bib73">Smith and Kortemme, 2010</xref>) samples rotamers of different amino acid residues at each position and returns a qualitative estimate of effects of substitutions on binding (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>). The Rosetta ‘flex_ddG’ protocol (<xref ref-type="bibr" rid="bib6">Barlow et al., 2018</xref>) quantitatively estimates effects of mutations on binding free energies for systematic mutations at each position (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="supplementary-material" rid="fig4sdata3">Figure 4—source data 3</xref>, <xref ref-type="supplementary-material" rid="fig4sdata4">Figure 4—source data 4</xref>), and has been shown to perform comparably to more computationally expensive alchemical free energy calculations for predicting mutational effects on protein-ligand affinities (<xref ref-type="bibr" rid="bib1">Aldeghi et al., 2018</xref>). As expected, substitutions at invariant positions P1 and I3 were generally predicted to be destabilizing, while changes to the solvent-exposed, degenerate x2 and x4 positions were predicted to have minimal effects (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Intriguingly, mutations within upstream and downstream residues were frequently predicted to enhance binding. Mutations to more hydrophobic or aromatic residues (W,F,Y,I,V) in the −1 position for the PVIVIT motif (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, left) or to most residues other than the native P-1 for the AKAP79 motif (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, right) improved binding in silico, as did mutations at Position eight to aromatic (F,Y), aliphatic (I, V, L), or acidic (D, E) residues (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The FoldX protocol uses an empirical force field to allow rapid evaluation of the effects of mutations on the free energy of protein folding and complex formation (<xref ref-type="bibr" rid="bib33">Guerois et al., 2002</xref>; <xref ref-type="bibr" rid="bib70">Schymkowitz et al., 2005</xref>). These calculations revealed globally similar results (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>, <xref ref-type="supplementary-material" rid="fig4sdata5">Figure 4—source data 5</xref>, <xref ref-type="supplementary-material" rid="fig4sdata6">Figure 4—source data 6</xref>), with mutations to conserved hydrophobic residues again predicted to be destabilizing and mutations to other residues predicted to have little effect. However, Rosetta predicted less deleterious effects for substituting glycine and proline residues, perhaps due to better local sampling of backbone conformations.</p><p>To determine the degree to which Rosetta and FoldX successfully predict observed mutational effects on binding, we generated scatter plots showing relationships between measured affinities and predicted frequencies or changes in free energy of binding (<inline-formula><mml:math id="inf29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>), respectively, for each residue at each position (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>; <xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>, <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6</xref>). All methods correctly predicted that I3 and I5 mutations decrease affinity; however, modeling approaches predicted that variations at solvent-exposed positions (V2 and V4) would have little effect on affinity, in direct contrast to experimental observations (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>, <xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>, <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6</xref>). Calculations of the fraction of residues correctly predicted to be either stabilizing (<inline-formula><mml:math id="inf30"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> &lt; 0) or destabilizing (<inline-formula><mml:math id="inf31"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> &gt; 0) by each algorithm at each position within the PVIVIT and AKAP79 peptides confirm relatively strong performance for buried hydrophobic residues with variable performance at other positions (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), with FoldX generally slightly outperforming Rosetta flex_ddG. These results highlight difficulties associated with properly modeling conformational changes in solvent-exposed and non-conserved positions, and show the utility of quantitative experimental measurements such as those presented here for improving binding models. Thermodynamic Integration and Free Energy Perturbation (TI/FEP) methods would likely enhance the ability to predict effects of mutating solvent-exposed residues, but are significantly more computationally expensive (<xref ref-type="bibr" rid="bib45">Kilburg and Gallicchio, 2016</xref>; <xref ref-type="bibr" rid="bib26">Gallicchio and Levy, 2011</xref>). Comparisons of MRBLE-pep measurements and Rosetta and FoldX predictions of the energetic effects of single site substitutions with orthogonal measurements are complicated by a lack of previously published affinity data. However, a direct comparison between MRBLE-pep measurements and computational predictions for two single-site substitutions in the PVIVIT motif reveal that only MRBLE-pep correctly discerns that a PVIVVT substitution has little effect while a PVIVIN substitution reduces binding (<xref ref-type="fig" rid="fig4s7">Figure 4—figure supplement 7</xref>).</p></sec><sec id="s2-8"><title>Absolute binding affinities confirm that mutations to flanking residues dramatically change affinities</title><p>To determine absolute affinities for peptides spanning a range of binding behaviors, we performed two experiments measuring concentration-dependent CN binding to an additional ‘calibration’ library containing ∼6 peptides from each core and flank library (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>). These experiments represented full technical replicates in which peptides were synthesized de novo on MRBLEs produced at different times and assayed for binding using different batches of purified calcineurin. Measured <inline-formula><mml:math id="inf32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> values relative to the PVIVIT variant between experiments showed strong agreement (Pearson r<sup>2</sup> = 0.72 (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>), demonstrating the robustness of the assay. Averaged absolute affinities estimated for all variants using these <inline-formula><mml:math id="inf33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> values and the known literature <inline-formula><mml:math id="inf34"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> for PVIVIT confirm that hydrophobic residues at position −1 and phosphorylated residues at position nine significantly increase affinity by 10-fold and 100-fold, respectively (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>).</p></sec><sec id="s2-9"><title>Identification of high-affinity scaffolds with therapeutic potential</title><p>Although cyclosporin A and FK506 are routinely prescribed to transplant patients to inhibit CN-dependent immune response activation, both drugs are associated with adverse effects that likely result from inhibition of CN-substrate dephosphorylation in non-immune tissues. While peptides themselves are rarely used as drugs, high-affinity peptides with increased specificity for a subset of CN-SLiM interactions could serve as initial scaffolds for downstream medicinal chemistry efforts to identify improved inhibitors. To probe for high-affinity variants, we measured CN binding to a final MRBLE-pep library containing the set of 36 ‘calibration’ peptides along with 11 peptides containing combinations of mutations discovered to increase affinity (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5</xref>, <xref ref-type="fig" rid="fig5s6">Figure 5—figure supplement 6</xref>, <xref ref-type="fig" rid="fig5s7">Figure 5—figure supplement 7</xref>, <xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>, <xref ref-type="supplementary-material" rid="fig5sdata4">Figure 5—source data 4</xref>). PVIVIT variants combining a phosphothreonine (Z) at position nine with hydrophobic residues (I, V) at position −1 showed the strongest binding, with measured <inline-formula><mml:math id="inf35"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values of ∼10 nM (50x stronger than the measured PVIVIT affinity), and multiple PVIVIT, PKIVIT, and AKAP79 variants also showed enhanced binding (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Measured <inline-formula><mml:math id="inf36"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>s for these full technical replicates showed remarkable agreement (r<sup>2</sup> = 0.83) (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), establishing the robustness and reproducibility of the assay.</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.40499.063</object-id><label>Figure 5.</label><caption><title>Calibrated <italic>in vitro</italic> affinities for a range of peptides.</title><p>(<bold>A</bold>) <italic>In vitro</italic> measurements of binding affinities for high-affinity binders identified by combining favorable residues. (<bold>B</bold>) Correlation between measured <inline-formula><mml:math id="inf37"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> values for a full technical replicate (new bead synthesis, new peptide synthesis, and new calcineurin protein purification) for the library shown in (<bold>A</bold>). Solid red line shows expected 1:1 linear relationship, dotted grey line shows linear regression of log-transformed values.</p><p><supplementary-material id="fig5sdata1"><object-id pub-id-type="doi">10.7554/eLife.40499.071</object-id><label>Figure 5—source data 1.</label><caption><title>Concentration-dependent binding for calibration library, replicate 1.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig5-data1-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><object-id pub-id-type="doi">10.7554/eLife.40499.072</object-id><label>Figure 5—source data 2.</label><caption><title>Concentration-dependent binding for calibration library, replicate 2.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig5-data2-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><object-id pub-id-type="doi">10.7554/eLife.40499.073</object-id><label>Figure 5—source data 3.</label><caption><title>Concentration-dependent binding for full calibration library, replicate 1.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig5-data3-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><object-id pub-id-type="doi">10.7554/eLife.40499.074</object-id><label>Figure 5—source data 4.</label><caption><title>Concentration-dependent binding for full calibration library, replicate 2.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig5-data4-v2.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.064</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Concentration-dependent binding for calibration peptide library, replicate 1.</title><p>Concentration-dependent binding measurements for selected peptides within the ‘calibration' library for the first experimental replicate. For each sequence, measured change in binding affinity relative to the wild-type PVIVIT sequence was determined by a global fit to a single-site binding model (black line); <inline-formula><mml:math id="inf38"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values were calculating from this <inline-formula><mml:math id="inf39"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and the known literature <inline-formula><mml:math id="inf40"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> for PVIVIT (0.5 μM) (<xref ref-type="bibr" rid="bib3">Aramburu et al., 1999</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.065</object-id><label>Figure 5—figure supplement 2.</label><caption><title>Concentration-dependent binding for calibration peptide library, replicate 2.</title><p>ConcentrationConcentration-dependent binding measurements for selected peptides within the ‘calibration' library for the second experimental replicate. For each sequence, measured change in binding affinity relative to the wild-type PVIVIT sequence was determined by a global fit to a single-site binding model (black line); <inline-formula><mml:math id="inf41"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values were calculating from this <inline-formula><mml:math id="inf42"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and the known literature <inline-formula><mml:math id="inf43"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> for PVIVIT (0.5 μM) (<xref ref-type="bibr" rid="bib3">Aramburu et al., 1999</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.066</object-id><label>Figure 5—figure supplement 3.</label><caption><title>Correlation between <inline-formula><mml:math id="inf44"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> measurements for calibration library technical replicates.</title><p>Correlation between <inline-formula><mml:math id="inf45"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> measurements for technical replicates of ‘calibration' libraries. Correlation between measured <inline-formula><mml:math id="inf46"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> values for a full technical replicate (new bead synthesis, new peptide synthesis, and new calcineurin protein purification) for the ‘calibration’ library. Solid red line shows expected 1:1 linear relationship, dotted grey line shows linear regression of log-transformed values.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig5-figsupp3-v2.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.067</object-id><label>Figure 5—figure supplement 4.</label><caption><title><inline-formula><mml:math id="inf47"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values for all peptides within calibration library.</title><p><inline-formula><mml:math id="inf48"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values for all peptides within calibration library. PVIVIT variants are shown in orange, PKIVIT variants are shown in green, NFATc2 variants are shown in red, and AKAP79 variants are shown in purple. Values are calculated using the average <inline-formula><mml:math id="inf49"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> value relative to PVIVIT for two technical replicates (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5</xref>, <xref ref-type="fig" rid="fig5s6">Figure 5—figure supplement 6</xref>) and the literature. <inline-formula><mml:math id="inf50"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> for PVIVIT (0.5 μM).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig5-figsupp4-v2.tif"/></fig><fig id="fig5s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.068</object-id><label>Figure 5—figure supplement 5.</label><caption><title>Concentration-dependent binding for full calibration library, replicate 1.</title><p>Concentration-dependent binding measurements for selected peptides within the ‘full calibration' library for the first replicate. For each sequence, measured change in binding affinity relative to the PVIVIT sequence was determined by a global fit to a single-site binding model (black line); <inline-formula><mml:math id="inf51"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values were calculating from this <inline-formula><mml:math id="inf52"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and the known literature <inline-formula><mml:math id="inf53"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> for PVIVIT (0.5 μM).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig5-figsupp5-v2.tif"/></fig><fig id="fig5s6" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.069</object-id><label>Figure 5—figure supplement 6.</label><caption><title>Concentration-dependent binding for full calibration library, replicate 2.</title><p>Concentration-dependent binding measurements for selected peptides within the ‘full calibration' library for the second replicate. For each sequence, measured change in binding affinity relative to the PVIVIT sequence was determined by a global fit to a single-site binding model (black line). <inline-formula><mml:math id="inf54"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values were calculating from this <inline-formula><mml:math id="inf55"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and the known literature for PVIVIT (0.5 μM).<inline-formula><mml:math id="inf56"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig5-figsupp6-v2.tif"/></fig><fig id="fig5s7" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40499.070</object-id><label>Figure 5—figure supplement 7.</label><caption><title>Correlation between <inline-formula><mml:math id="inf57"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> measurements for core/flank library measurements and ‘calibration’ library measurements.</title><p>Correlation between <inline-formula><mml:math id="inf58"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> measurements for core/flank library measurements and ‘calibration’ library measurements. Solid red line shows expected 1:1 linear relationship, dotted grey line shows linear regression of log-transformed values.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig5-figsupp7-v2.tif"/></fig></fig-group></sec><sec id="s2-10"><title>Quantitative comparisons between <italic>in vitro</italic> affinities and <italic>in vivo</italic> inhibition via calcineurin activity assays</title><p>The ultimate goal of mapping CN-SLiM binding energy landscapes is to improve understanding of CN target substrate recognition and enable rational design of <italic>in vivo</italic> inhibitors. To test the degree to which <italic>in vitro</italic> MRBLE-pep affinities predict <italic>in vivo</italic> inhibition, we used a previously developed dual luciferase reporter assay to assess the activity of the NFAT2 transcription factor in HEK293T cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) (<xref ref-type="bibr" rid="bib32">Grigoriu et al., 2013</xref>). NFAT2 must be dephosphorylated by CN to accumulate in the nucleus, where it activates transcription of its target genes, and this interaction can be inhibited by peptides or small molecules that binds to CN. Reduction of NFAT2-dependent transcriptional activity upon expression of a competing PxIxIT peptide therefore reflects, quantitatively, the affinity of the inhibitor peptide for CN. Candidate PxIxIT inhibitors were co-expressed as GFP-fusion proteins within cells to enhance their stability and <bold>facilitate</bold> direct measurement of inhibitor concentrations.</p><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.40499.075</object-id><label>Figure 6.</label><caption><title><italic>In vivo</italic> assays to quantify CN inhibition and an <italic>in vitro</italic> search for a potent inhibitor.</title><p>(<bold>A</bold>) <italic>In vivo</italic> experimental assay schematic. (<bold>B</bold>) Reporter gene inhibition in the presence of an empty eGFP vector (control), an empty eGFP vector with topical application of FK506, and vectors expressing PVIVIT, PKIVIT, NFATc2, and AKAP79 PxIxIT peptides with a C-terminal eGFP tag. (<bold>C</bold>) Reporter gene inhibition in the presence of various PVIVIT-, AKAP79-, and NFATc2-eGFP variants. (<bold>D</bold>) Reporter gene inhibition in the presence of various PKIVIT-eGFP variants. (<bold>E</bold>) <italic>In vitro</italic> calibrated binding affinities (<inline-formula><mml:math id="inf59"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, nM) plotted against relative <italic>in vivo</italic> activation for data shown in panels B (orange), C (green), and D (blue).</p><p><supplementary-material id="fig6sdata1"><object-id pub-id-type="doi">10.7554/eLife.40499.076</object-id><label>Figure 6—source data 1.</label><caption><title>Initial <italic>in vivo</italic> experiment.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig6-data1-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><object-id pub-id-type="doi">10.7554/eLife.40499.077</object-id><label>Figure 6—source data 2.</label><caption><title>PKIVIT <italic>in vivo</italic> experiment.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig6-data2-v2.csv"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><object-id pub-id-type="doi">10.7554/eLife.40499.078</object-id><label>Figure 6—source data 3.</label><caption><title>All other peptides <italic>in vivo</italic> experiment.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-40499-fig6-data3-v2.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-40499-fig6-v2.tif"/></fig><p>We compared levels of NFAT-driven luciferase activity in the presence of empty vector, vectors driving expression of the 4 PxIxIT peptide scaffolds probed extensively <italic>in vitro</italic> (PVIVIT, PKIVIT, NFATc2, and AKAP79), or FK506, a small-molecule inhibitor of CN with a previously measured IC50 of ∼0.5 nM ( <xref ref-type="fig" rid="fig6">Figure 6B</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig6sdata2">Figure 6—source data 2</xref>, <xref ref-type="supplementary-material" rid="fig6sdata3">Figure 6—source data 3</xref>) (<xref ref-type="bibr" rid="bib25">Fruman et al., 1992</xref>). All 4 PxIxIT peptides substantially inhibited NFAT-driven luciferase activity, confirming competitive inhibition of CN-NFAT-(PxIxIT) binding <italic>in vivo</italic>. Consistent with MRBLE-pep measurements, PKIVIT was the most effective inhibitor, followed closely by PVIVIT. NFATc2 and AKAP79 showed weaker <italic>in vivo</italic> inhibition, consistent with MRBLE-pep results and in contrast with prior work suggesting that AKAP79 binds with equal affinity to PVIVIT (<inline-formula><mml:math id="inf60"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>∼500 nM) (<xref ref-type="bibr" rid="bib53">Li et al., 2012</xref>). Co-expression of the PKIVIT peptide resulted in greater inhibition than FK506, which interferes with CN-substrate interactions by occluding the LxVP-SLiM binding site (<xref ref-type="bibr" rid="bib66">Rodríguez et al., 2009</xref>) and is a potent CN inhibitor.</p><p>We next examined the importance of PxIxIT flanking residues by creating substitutions in the −1 and 9 positions (<xref ref-type="fig" rid="fig6">Figure 6C,D</xref>). Consistent with in silico predictions and MRBLE-pep affinities, substitution of a hydrophobic residue (IPKIVIT or LPRIEIT) at the −1 position significantly increased inhibition, whereas incorporating an acidic residue (EPKIVIT or DPRIEIT) greatly diminished inhibition. As predicted computationally and observed in the MRBLE-pep assays, introduction of the phosphomimetic mutation H9D resulted in slightly increased inhibition; it was not possible to directly test the extremely high affinity phosphoserine or phosphothreonine <italic>in vivo</italic>. Taken together, in silico modeling, the MRBLE-pep affinities, and <italic>in vivo</italic> results suggest that phosphorylation at position nine may be a key determinant of modulating PxIxIT-CN affinity.</p><p>Finally, we sought to test whether MRBLE-pep <italic>in vitro</italic> affinity measurements could identify initial peptide scaffolds exhibiting strong inhibition <italic>in vivo</italic> for future optimization as peptide or small-molecule inhibitors. PKIVIT was a significantly stronger <italic>in vivo</italic> inhibitor than the previously patented PVIVIT peptide (<xref ref-type="bibr" rid="bib59">Nakamura et al., 2007</xref>), with activity comparable to the PKIIIT site within the known A238L inhibitor. As predicted, both the IPKIVITGPH and HPKIVITGPD variants exhibited even stronger binding and inhibition (<xref ref-type="fig" rid="fig6">Figure 6D</xref>); similarly, mutating the I1 and A2 residues in the AKAP79 PIAIIIT motif to create a novel PxIxIT sites with adjacent prolines and a positively charged residue in the second position (PPKIIIT) greatly enhanced inhibition. Overall, MRBLE-pep <italic>in vitro</italic> measurements were strongly predictive of <italic>in vivo</italic> inhibition (<xref ref-type="fig" rid="fig6">Figure 6E</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we demonstrate a novel strategy to quantitatively profile parts of the binding specificity landscape for a peptide-protein interaction, thereby generating key insights required to map and model essential signaling networks in healthy and diseased cells. Our approach is complementary to current techniques, with the potential to provide new insights into SLiM recognition and function throughout signaling networks. Yeast and phage display can powerfully discriminate between ‘bound’ and ‘unbound’ peptide populations (<xref ref-type="bibr" rid="bib7">Bazan et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Cherf and Cochran, 2015</xref>) for &gt; 10<sup>8</sup> protein-peptide interactions, and array-based methods can return information about qualitative binding strengths for many protein-peptide interactions in parallel. However, neither method can return the quantitative thermodynamic constants (dissociation constants (K<sub>d</sub>s) and relative binding energies (<inline-formula><mml:math id="inf61"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>s) essential for predicting protein occupancies <italic>in vivo</italic> and effects on downstream signaling responses. For display- and array-based screens, measurements take place far from equilibrium, biasing recovered interactions towards the strongest binding motifs and losing information about those interactions with <inline-formula><mml:math id="inf62"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>s close to physiological concentrations most likely to be dynamically regulated <italic>in vivo</italic>.</p><p>The MRBLE-pep assay is faster and requires less in material than alternative low-throughput quantitative methods: measuring interaction affinities for 384 peptides using MRBLE-pep requires ∼400x, ∼700x, and ∼2000x less purified protein than surface plasmon resonance, fluorescence polarization, and isothermal calorimetry, respectively, with savings increasing with library size (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). This reduction in material should allow future profiling of a wide range of biologically important SLiM-binding domains, including those that are uncharacterized, unstable, and/or difficult to express recombinantly. MRBLE-pep libraries can be synthesized, assayed, and imaged in days, facilitating iterative rounds of synthesis and measurement for efficient affinity landscape mapping as well as testing and refining computational prediction algorithms. After screening large sequence spaces for candidate interaction motifs, MRBLE-pep can be used to quickly and efficiently scan through thousands of potential SLiMs to validate true hits, measure affinities for these hits in high-throughput, and systematically perturb amino acids within motifs to derive a position-specific affinity matrix that can be used to predict additional candidate downstream targets <italic>in vivo</italic>. Moreover, the ability to tune the density of applied peptides enables fast optimization to probe the affinity range of interest as well as test for surface density-induced binding artifacts. An elegant ‘hold-up’ assay that couples high-throughput affinity purification to microfluidic gel electrophoresis recently demonstrated a similar ability to measure relative affinities for 400 domain-peptide pairs (<xref ref-type="bibr" rid="bib82">Vincentelli et al., 2015</xref>). However, this method requires considerably more infrastructure than the MRBLE-pep assay and has not yet been used in subsequent work. In future work, the MRBLE-pep platform could be combined with a simple and portable imaging device to allow labs to employ the assay with only standard laboratory equipment (<italic>e.g.</italic> pipettes and a benchtop centrifuge).</p><p>MRBLE-pep measurements can also be combined with data from high-throughput <italic>in vivo</italic> methods to decipher the structure and wiring of cellular signaling networks. Yeast two-hybrid (Y2H) assays and affinity purification coupled to mass spectrometry (AP-MS) techniques have revealed tens of thousands of new interactions within the human interactome (<xref ref-type="bibr" rid="bib67">Rolland et al., 2014</xref>; <xref ref-type="bibr" rid="bib38">Huttlin et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Huttlin et al., 2017</xref>). However, SLiM-mediated binding interactions remain statistically underrepresented in these datasets (<xref ref-type="bibr" rid="bib61">Neduva and Russell, 2006</xref>; <xref ref-type="bibr" rid="bib81">Van Roey et al., 2014</xref>; <xref ref-type="bibr" rid="bib15">Davey et al., 2012</xref>), likely due to fast dissociation rates, and AP-MS results cannot distinguish between binary interactions and higher-order complexes, and provide no direct information about the motif involved. MRBLE-pep measurements of peptides tiled across candidate interacting proteins could confirm candidate interactors, identify the SLiMs responsible, and determine whether a candidate interaction is direct or indirect. In particular, the ability to return information about residues that ablate binding can significantly improve the ability to predict true targets <italic>in vivo</italic> (<xref ref-type="bibr" rid="bib46">Krystkowiak et al., 2018</xref>). To test candidate inhibitor specificities, MRBLE-pep could profile binding of a broad set of cellular proteins against high-affinitiy inhibitors with unnatural amino acids returned from recently developed high-throughput mass spectrometry-based (LC/MS/MS) approaches (<xref ref-type="bibr" rid="bib27">Gates et al., 2018</xref>; <xref ref-type="bibr" rid="bib83">Vinogradov et al., 2017</xref>).</p><p>Beyond the method itself, our findings reveal biologically significant insights into CN-PxIxIT specificity and illustrate how systematic analyses can shed light on elusive SLiM-protein interactions. The MRBLE-pep data and <italic>in vivo</italic> validation presented here are the first to reveal the impact of PxIxIT flanking residues on affinity, allowing identification of several peptides whose affinity for CN is two orders of magnitude higher than that of the highest affinity known substrate (PVIVIT) and potently inhibit CN-NFAT signaling <italic>in vivo</italic>. We reveal the presence of significant epistasis between residues, including one interaction important for the high affinity of a known CN inhibitor (A238L) (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Finally, we provide affinity measurements for a collection of peptides based on different known PxIxIT scaffolds with a wide variety of affinities, yielding a tool kit of peptide sequences that can be used to probe CN recognition and function <italic>in vivo</italic>.</p><p>In addition to identifying candidate peptides for manipulation of CN signaling, this first demonstration that residues both upstream and downstream contribute to PxIxIT-CN affinity redefines the motif itself. Current computational strategies attempt to identify novel CN substrates by searching for sequences within the proteome that match a consensus for the six core residues alone. The expanded 10-residue definition of the PxIxIT motif derived here will significantly enhance future computational efforts to comprehensively map the CN signaling network, reducing the number of both false positive and false negative substrates. In addition, MRBLE-pep provides critical Information about residues that reduce affinity (<italic>e.g.</italic> acidic residues at the −1 position reduces affinity) that is never revealed by positive screening methods and is rarely collected due to the resource-intensive nature of such analyses using established techniques. The ability to predict affinity based on SLiM sequence is an essential step toward accurate modeling of signaling dynamics <italic>in vivo</italic>, as the extent of <italic>in vivo</italic> dephosphorylation has previously been shown to depend on primary PxIxIT amino acid sequence (and the associated interaction affinity) (<xref ref-type="bibr" rid="bib68">Roy et al., 2007</xref>). Even subtle (∼2-fold) differences in binding could have profound effects on downstream signaling under physiologic conditions given the low affinities of CN-PxIxIT interactions.</p><p>Establishing the impact of post translational modifications on SLiM-protein affinity is critical for understanding cross talk between signaling networks <italic>in vivo</italic>. Consistent with our findings that acidic residues at the −1 position decrease affinity, JNK kinase regulates CN signaling by phosphorylating a serine that immediately precedes the PxIxIT of NFAT4 (<xref ref-type="bibr" rid="bib14">Chow et al., 2000</xref>). Similarly, our demonstration that phosphorylated residues downstream of the core PxIxIT sequence at position nine enhance PVIVIT affinity echoes observations that phosphorylation of a threonine in this position is required for binding of CN to a PxIxIT site in C16ORF74, and for its ability to promote invasiveness of pancreatic ductal adenocarcinoma (PDAC) (<xref ref-type="bibr" rid="bib60">Nakamura et al., 2017</xref>). This positive effect on binding is context-dependent, increasing PVIVIT binding 50-fold but having little or no effect on other PxIxIT sequences, reinforcing the importance of systematic analyses for generating predictive information.</p><p>Beyond improving the ability to reconstruct downstream CN signaling networks <italic>in vivo</italic>, these results also have direct relevance to precision medicine. Current annotations of 2RQ, 7 PA, and 7PL missense mutations within the NFATc2 PxIxIT site recovered from sequenced lung and breast adenocarcinomas describe them as unlikely to have functional effects <italic>in vivo</italic> (<xref ref-type="bibr" rid="bib11">cBioPortal, 2018</xref>). While the experiments presented here did not directly test the functional consequences of a R2Q mutation, all mutations away from the native residue at this position resulted in a dramatic loss of binding (<xref ref-type="fig" rid="fig3s17">Figure 3—figure supplement 17</xref>), and the P7A substitution led to a nearly complete loss of binding (<xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref>, <xref ref-type="fig" rid="fig3s17">Figure 3—figure supplement 17</xref>, <xref ref-type="fig" rid="fig3s18">Figure 3—figure supplement 18</xref>). Thus, binding specificity maps like those obtained here could both help clinicians identify functionally significant missense mutations, and refine the computational algorithms that predict the impact of such alleles. Overall, the approaches outlined here will help decipher the language of SLiM-domain binding events, and of the cellular signaling networks they define in both healthy and diseased cells.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><p>Reagents for peptide synthesis were purchased and used without further purification from NovaBiochem, AnaSpec (Fremont, CA), and Sigma-Aldrich (St. Louis, MO). All other solvents and chemical reagents were purchased from Sigma-Aldrich.</p><sec id="s4-1"><title>MRBLE synthesis and collection</title><p>MRBLEs were synthesized using a previously published microfluidic device (<xref ref-type="bibr" rid="bib28">Gerver et al., 2012</xref>; <xref ref-type="bibr" rid="bib62">Nguyen et al., 2017a</xref>; <xref ref-type="bibr" rid="bib63">Nguyen et al., 2017b</xref>) with each code collected into wells of a 96-well plate using an open-source in-house fraction collector. Briefly, all lanthanide input mixtures contained double-distilled water (ddH<sub>2</sub>O), 42.8% v/v 700 MW PEG-diacrylate (PEG-DA) (Sigma-Aldrich), 19.6 mg mL<sup>−1</sup> lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP), and 5.0% v/v YVO4:Eu (at 25 mg mL<sup>−1</sup>). Individual input mixtures contained 16.3% v/v of either YVO4:Sm (25 mg mL<sup>−1</sup>), YVO4:Dy (25 mg mL<sup>−1</sup>), or YVO4:Tm (12.5 mg mL<sup>−1</sup>). Lanthanide solutions were mixed using a herringbone mixer channel and forced into droplets using a T-junction with a continuous stream of HFE7500 (3M Novec) containing 2% w/w modified ionic Krytox 157FSH (Miller Stephenson, Danbury, CT) (<xref ref-type="bibr" rid="bib17">DeJournette et al., 2013</xref>). Droplets were then photopolymerized with UV light from a full-spectrum 200W Xenon arc lamp (Dymax, Torrington, CT, USA). With this setup, ∼3000 beads containing each spectral code were synthesized in 70 s (as described previously <xref ref-type="bibr" rid="bib28">Gerver et al., 2012</xref>; <xref ref-type="bibr" rid="bib62">Nguyen et al., 2017a</xref>); for the 48-plex MRBLE library used here, each code was produced 10 times to yield ∼30,000 beads per code.</p></sec><sec id="s4-2"><title>Bead functionalization</title><p>MRBLE hydrogel beads were functionalized with terminal amine handles via Michael addition by reacting available acrylates in the MRBLEs with a solution of cysteamine (50 eq) containing pyridine (50 eq) in H2O:DMF (1:3) for 18 hr at ambient temperature. Next, to selectively functionalize outer and inner regions, MRBLEs were swelled in water overnight and drained using a manifold before the addition of a solution containing Fmoc-N-hydroxysuccinimide (0.2 eq) and diisopropylethylamine (DIPEA) (0.8 eq) in dichloromethane:diethyl ether (55:45) with vigorous shaking (1600 rpm for 15 s followed by 30 s at rest) for 30 min (<xref ref-type="bibr" rid="bib54">Liu et al., 2002</xref>). To selectively functionalize MRBLE inner core regions with an acid-labile rink amide linker, MRBLEs were then treated with 4-[(2,4-Dimethoxyphenyl)(Fmoc-amino)methyl]phenoxyacetic acid (rink amide) (5.0 eq), N,N′-Diisopropylcarbodiimide (DIC) (5.0 eq), and DIPEA (10 eq) in dimethylformamide (DMF) for 1 hr and repeated twice. After removal of the Fmoc protecting group using 20% 4-methylpiperidine (4-MP) in DMF for 20 min, the effective on-bead peptide concentration was reduced by reacting the bead with a mixture of Fmoc-glycine-OH:Ac-N-glycine-OH (1:9) (5.0 eq), DIC(5.0 eq), and DIPEA (10 eq) for 14 hr. Following Fmoc deprotection, MRBLEs were transferred to an automated peptide synthesizer for solid phase peptide synthesis (SPPS).</p></sec><sec id="s4-3"><title>On-bead peptide synthesis</title><p>Peptide synthesis was performed using a Biotage Syro II automated peptide synthesizer following instructions from the manufacturer (Biotage, Charlotte, NC). During coupling steps, Fmoc-protected amino acids (10 eq) were activated with HCTU (9.8 eq) and NMM (20 eq) with coupling times of 8 min for standard amino acids and 25 min for phosphorylated amino acids. Each coupling round comprised of 2 sequential coupling reactions with the addition of fresh amino acid and coupling reagents. Deprotection was performed initially with 40% 4-MP for 2 min and then followed with 20% 4-MP for an additional 6 min. MRBLEs were then washed thoroughly with 6 rounds of DMF (0.4 mL) before the next coupling step. Before global deprotection with TFA, 50 µL from a volume of 400 µL for each code was saved for biotin conjugation (as described below). To perform the global deprotection step, MRBLEs were washed with DCM and dried under vacuum before the addition of 0.5 mL of TFA cocktail (Reagent B, TFA:phenol:ddH2O:triisopropylsilane, 88:5:5:2, v/m/v/v) was added to each reaction tube and reacted with shaking (15 s shaking and 1 min rest) for 1.5 hr. After TFA deprotection, MRBLEs containing deprotected peptides were washed with TFA (~0.5 mL, and collected for MALDI analysis), DCM (~2 mL), neutralized with 10% DIPEA in DMF twice (~1 mL), and then finally washed with storage buffer (1 mL, 0.1% TBST with 0.02% NaN3) 3 times (<xref ref-type="bibr" rid="bib47">Kumaresan et al., 2011</xref>). To assess peptide quality, the TFA solution containing cleaved/unprotected peptide was transferred to 15 mL falcon tubes using the provided liquid transfer system from Biotage. Peptides were triturated with cold diethylether (~1 mL), pelleted, decanted, and repeated these steps 3 times before preparing for MALDI analysis using a general protocol described below.</p></sec><sec id="s4-4"><title>Peptide concentration estimation via biotin conjugation assay</title><p>A small aliquot (~50 μL from 400 μL) of each code was transferred and pooled into a separate fritted reaction tube (Biotage 2 mL reaction tubes for SPPS) for biotin (50 eq) conjugation using DIC (50 eq), DIPEA (100 eq), and DMF overnight. After washing the MRBLEs (DMF, MeOH, and DCM), another round of coupling using the same conditions mentioned above was mixed for 2 hr and then washed. MRBLEs with terminal biotin were then globally deprotected using a cocktail of TFA/phenol/H2O/TIPS (87.5:5:5:2.5 v/v) at ambient temperature for 1.5 hr. After global deprotection, MRBLEs were neutralized with 10% DIPEA in DMF, washed with DCM, washed with 3 X PBS containing 0.1% TWEEN 20 (0.1% PBST), and stored in 0.1% PBST containing 0.02% NaN3. After biotin conjugation, a 40 μL aliquot from a 600 μL suspension of beads was passivated with 0.1% PBST containing 5% BSA in a 150 μL PCR strip tube on a rotator overnight at ~5 °C. The beads were then washed with 0.1% PBST containing 2% BSA 3 times (~100 μL), followed by incubation with 1 μL of labeled streptavidin (final concentration = ~189 nM, Abcam, ab134241) in 0.1% PBST containing 2% BSA (99 μL) for 30 min on a rotator at ambient temperature. After incubation, MRBLEs were pelleted and washed with 0.1% PBST once and then imaged to obtain binding data.</p></sec><sec id="s4-5"><title>MALDI quality control</title><p>After global deprotection, supernatants collected in 15 mL Falcon tubes for each code were placed into a freezer for 1 hr; these tubes were then centrifuged (4000 g for 20 min at 4 °C) and decanted (repeated 3 times). Peptides were then dissolved with 60% ACN/H2O (20 μL, phosphopeptides were dissolved with 50% acetic acid) for MALDI analysis using THAP (250 mM in ACN) as the matrix. To prepare the MALDI plate (microScout Target MSP 96 target polished steel BC, part #8280800), 0.5 μL of sodium citrate (250 mM in H2O containing 0.1% TFA) was spotted on to the plate surface and allowed to dry. After drying, 1 μL of a 1:1 mixture of the peptide solution with a solution of sodium citrate:THAP (1:1) was spotted onto the plate and allowed to dry again before analysis. Data was obtained using a Bruker microflex MALDI-TOF (Billerica, MA, USA). The instrument was run on positive-ion reflector mode with a laser setting of 1,810 V and data averaged over 100 scans. Raw data was analyzed using FlexAnalysis and mMass (ver. 5.5, <ext-link ext-link-type="uri" xlink:href="http://www.mmass.org/">http://www.mmass.org/</ext-link>).</p></sec><sec id="s4-6"><title>Purification of calcineurin</title><p>N-terminally, 6-His-tagged human calcineurin A isoforms (truncated at residue 400), either wild-type or containing the mutation 330NIR333-AAA, were expressed in tandem with the calcineurin B subunit in <italic>E. coli</italic> BL21 (DE3) cells (Invitrogen) and cultured in LB medium containing carbenicillin (50 mg/ml) at 37°C to mid-log phase. Expression was induced with 1 mM isopropyl 1-thio-b-galactosidase at 16°C for 18 hr. Cells were pelleted, washed and frozen at −80°C for at least 12 hr. Thawed cell pellets were re-suspended in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20, 1 mM <inline-formula><mml:math id="inf63"><mml:mi>β</mml:mi></mml:math></inline-formula>-mercapto ethanol, protease inhibitors) and lysed by sonication using four 1 min pulses at 40% output. Extracts were clarified using two rounds of centrifugation (20,000 X g, 20 min) and then bound to 1 ml of Ni-NTA beads in lysis buffer containing 5 mM imidazole. Beads were washed with lysis buffer containing 20 mM imidazole and eluted with lysis buffer containing 300 mM imidazole. Purified calcineurin heterodimer were dialyzed in buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM <inline-formula><mml:math id="inf64"><mml:mi>β</mml:mi></mml:math></inline-formula>-mercapto ethanol) and stored in 10–15% glycerol at −80°C.</p></sec><sec id="s4-7"><title>Bead and antibody imaging</title><p>MRBLEs were imaged by transferring 20 μL of suspended beads (entire volume) onto a quartz microscope slide (Electron Microscopy Sciences, quartz microscope slide, 75 mm x 25 mm, 1 mm thick, cat. #72250–03), placing an additional quartz coverslip (Electron Microscopy Sciences, quartz coverslip, 25 mm x 25 mm, 1 mm thick, cat. #72256–02) onto the droplet, and then depositing mineral oil around the edges of the coverslip to prevent the sample from drying out during imaging. MRBLEs were imaged largely as described previously (<xref ref-type="bibr" rid="bib62">Nguyen et al., 2017a</xref>) in 11 channels: a bright field channel, a Cy5 fluorescence channel (using a SOLA light engine for excitation), and nine additional lanthanide channels (435, 474, 536, 546, 572, 620, 630, 650, 780 nm, with exposure times of 500, 1000, 500, 500, 375, 150, 75, 225, 2000 ms, respectively; Semrock, Rochester, NY) using excitation illumination generated by a Xenon arc lamp (Lambda SL, Sutter Instrument, Novato, CA) and directed through a 292/27 nm bandpass filter (Semrock, Rochester, NY) via a UV-liquid light guide (Sutter Instrument, Novato, CA) mounted in place of the condenser using a custom 3D printed holder.</p></sec><sec id="s4-8"><title>Image processing (code calling)</title><p>Bead images were processed using a custom-built open-source Python software package freely available through PyPI and GitHub and regularly maintained (<xref ref-type="bibr" rid="bib35">Harink et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Harink, 2018</xref>). Briefly, MRBLE boundaries were identified from bright field images, followed by quantification of median lanthanide intensities in each channel to identify embedded MRBLE codes. CN binding was then quantified for each MRBLE by calculating the median fluorescence intensity for bound protein associated with the outer shell of the MRBLE.</p></sec><sec id="s4-9"><title>Calcineurin binding assays (time series and dilution series)</title><p>Pre-incubation of CN with anti-His antibody significantly reduced observed background binding to sequences containing multiple basic residues due to cross-reactivity of anti-His antibody (<xref ref-type="fig" rid="fig3s9">Figure 3—figure supplement 9</xref>, <xref ref-type="fig" rid="fig3s10">Figure 3—figure supplement 10</xref>, <xref ref-type="fig" rid="fig3s11">Figure 3—figure supplement 11</xref>, <xref ref-type="fig" rid="fig3s12">Figure 3—figure supplement 12</xref>). Therefore, CN:α−6xHis antibody-DyLight-650 complex (2.5 μM, CN:αHisAb650, Abcam ab117504) was prepared by pre-incubating 6x-His-tagged CN with equal concentration of αHisAb650 in CN buffer at ∼5 °C for 1 hr. MRBLEs were prepared by transferring a 20 μL aliquot from a 600 μL suspension (∼3000–8000 beads depending on pellet size) to a 100 μL PCR strip (20 μL for each CN concentration), exchanging buffer via 3 cycles of iterative pelleting, decanting, and resuspension with 0.1% PBST containing 5% BSA, pH = 7.5 (100 μL), and then left mixing at ∼5 °C on a rotator in the same wash buffer overnight (∼14 hr). MRBLEs were then buffer exchanged once again with CN binding buffer (50 mM Tris pH = 7.5, 150 mM NaCl, 0.1% TWEEN 20) via three iterative cycles of pelleting, decanting, and resuspension.</p><p>To perform binding assays, the CN:αHisAb650 complex (at 2.5 μM) was serially diluted into tubes containing BSA-passivated MRBLEs and CN buffer (2 μM, 1μM, 500 nM, 250 nM, 125 nM, 62.5 nM) and incubated for 5 hr on a rotator at ∼5 °C. After incubation, MRBLEs were pelleted, decanted, and washed once with 0.1% PBST (100 μL). After a final round of pelleting and decanting, 20 μL of 0.1% PBST was added and the beads were transferred to a quartz microscope slide for imaging. To confirm equilibrium conditions, we measured CN:MRBLE interactions for six peptides after incubation times ranging from 30 min to 24 hr. Binding appeared to reach equilibrium after ∼5 hr (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), so all following experiments were performed after an incubation time of 5–6 hr.</p></sec><sec id="s4-10"><title>Affinity modeling (competitive binding assay)</title><p>The affinity (<inline-formula><mml:math id="inf65"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>) for each peptide in a MBRLE library was determined via a two-step nonlinear regression using a single-site binding model:<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>⁢</mml:mo><mml:mi>a</mml:mi><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mi>C</mml:mi><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>⁢</mml:mo><mml:mi>o</mml:mi><mml:mo>⁢</mml:mo><mml:mi>t</mml:mi><mml:mo>⁢</mml:mo><mml:mi>a</mml:mi><mml:mo>⁢</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mi>C</mml:mi><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>⁢</mml:mo><mml:mi>o</mml:mi><mml:mo>⁢</mml:mo><mml:mi>t</mml:mi><mml:mo>⁢</mml:mo><mml:mi>a</mml:mi><mml:mo>⁢</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="inf66"><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> is the median measured fluorescence intensity for each peptide, <inline-formula><mml:math id="inf67"><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the dissociation constant for that interaction, [<inline-formula><mml:math id="inf68"><mml:mrow><mml:mi>C</mml:mi><mml:mo>⁢</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>⁢</mml:mo><mml:mi>o</mml:mi><mml:mo>⁢</mml:mo><mml:mi>t</mml:mi><mml:mo>⁢</mml:mo><mml:mi>a</mml:mi><mml:mo>⁢</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>] is total CN concentration, and <inline-formula><mml:math id="inf69"><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>⁢</mml:mo><mml:mi>a</mml:mi><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is a global variable representing the fluorescence intensity once MRBLE-pep beads are saturated. First, we determined the global saturation value (<inline-formula><mml:math id="inf70"><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>⁢</mml:mo><mml:mi>a</mml:mi><mml:mo>⁢</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>), by globally fitting the top 80% highest-intensity MRBLE codes. Next, we globally fit the entire data set using this <italic><inline-formula><mml:math id="inf71"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></italic> value to yield an estimated absolute affinity (<inline-formula><mml:math id="inf72"><mml:msub><mml:mi>K</mml:mi><mml:mi>d</mml:mi></mml:msub></mml:math></inline-formula>) for all peptides in the library. Given that the estimated peptide concentration in these assays (20 nM/x, where x represents the number of species probed) is significantly lower than estimated <italic><inline-formula><mml:math id="inf73"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></italic> values of these interactions, we make the approximation <inline-formula><mml:math id="inf74"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>C</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo>≈</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>C</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>. Differences in binding affinity were calculated relative to a reference peptide using the standard equation:<disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>⁢</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>⁢</mml:mo><mml:mi>G</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mi>R</mml:mi><mml:mo>⁢</mml:mo><mml:mi>T</mml:mi><mml:mo>⁢</mml:mo><mml:mi>l</mml:mi><mml:mo>⁢</mml:mo><mml:mi>n</mml:mi><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mi>r</mml:mi><mml:mo>⁢</mml:mo><mml:mi>e</mml:mi><mml:mo>⁢</mml:mo><mml:mi>f</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>To calibrate measured affinities across multiple assays, we first determined an absolute affinity for a single high-affinity reference peptide (MAGPHPVIVITGPHEE) using the mean of the ‘Triplicate low’ value (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), ‘Triplicate high’ value (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), and value from a binding assay in which this peptide appeared alone (data not shown, <italic><inline-formula><mml:math id="inf75"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></italic> = 980 nM). Next, we used this reference value and calculated differences in binding affinity (<inline-formula><mml:math id="inf76"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>) to estimate absolute <italic><inline-formula><mml:math id="inf77"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></italic> values for each peptide within the calibration and full calibration libraries (<xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>, <xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>, <xref ref-type="supplementary-material" rid="fig5sdata4">Figure 5—source data 4</xref>).</p></sec><sec id="s4-11"><title>Rosetta-based ‘Sequence Tolerance' method</title><p>For estimating tolerated amino acid substitutions at each position in the two available CN-PxIxIT co-crystal structures with well-defined electron density (positions −1 to 9 of the PxIxIT motif) we used the generalized sequence tolerance module of the Rosetta Backrub server available at <ext-link ext-link-type="uri" xlink:href="https://kortemmeweb.ucsf.edu/backrub%20">https://kortemmeweb.ucsf.edu/backrub</ext-link> (<xref ref-type="bibr" rid="bib74">Smith and Kortemme, 2011</xref>). Briefly, the protocol samples amino acid residues in different rotameric conformations on backbone ensembles generated using Rosetta Backrub simulations and records low energy amino acid sequences, from which amino acid frequencies of tolerated substitutions are derived. In contrast to the published protocol, we modified only one position in the peptide at a time, to more closely mimick the experimental measurements. We used ensembles of 100 backbone structures with a <italic>kT</italic> value of 0.228; self-energies and interchain interaction energies were reweighted using the default scaling factors of 0.4 and 1, respectively.</p></sec><sec id="s4-12"><title>Rosetta-based method for estimating the energetic effects of amino acid substitutions (‘flex_ ddG’)</title><p>To estimate changes in binding energy upon mutation (<inline-formula><mml:math id="inf78"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>), we used the Rosetta flex_ddG protocol (<xref ref-type="bibr" rid="bib6">Barlow et al., 2018</xref>). We systematically substituted all twenty natural amino acids at each position (−1:9) for the two peptides with available crystal structures bound to calcineurin (CN-PVIVIT, CN-IAIIIT), with the remaining positions restricted to the wild-type amino acid residues in each crystal structure. Briefly, the flex_ddG protocol uses the Rosetta Talaris 2014 energy function, minimization with harmonic restraints, Rosetta Backrub simulations to generate conformational ensembles, mutation and optimization of side chain conformations, and another final retrained minimization step. We followed the protocol published in <xref ref-type="bibr" rid="bib6">Barlow et al. (2018)</xref>, except using 10,000 Backrub steps instead of the default value of 35,000 steps.</p></sec><sec id="s4-13"><title>FoldX calculations to estimate the energetic effects of amino acid substitutions</title><p>To prepare systems for analysis with FoldX, we obtained the PDB entries for calcineurin bound to a PVIVIT peptide (PDB entry 2P6B) and bound to a IAIIIT peptide (PDB entry 3LL8). We then deleted chains C and D, as well as accessory ions and waters, from both structures. In the 2P6B structure, we also removed residues Pro4, Glu16 and the -NH2 cap to match the resolved portions of the peptide present in the 3LL8 structure. We used two FoldX commands to perform the FoldX calculations. First, we ran the RepairPDB command on each system with default options to generate structures in a suitable format for the subsequent step. Second, for each mutation, we ran the BuildModel command for 10 iterations. We then extracted delta-delta Gs from the automatically generated output file that reported differences in the delta Gs between wild type and mutant. Data values in <xref ref-type="fig" rid="fig4">Figure 4</xref> correspond to median value of the delta-delta Gs for each of the ten iterations for a given mutant.</p></sec><sec id="s4-14"><title><italic>In vivo</italic> calcineurin activity assay</title><p>PxIxIT peptides were fused to eGFP in pEGFPc1 vector. HEK293T cells were transfected with pEGFPc1 clones, pNFAT-Luc and CMV-Renilla in a 6-well plate format. 18 hr post transfection, 1μM FK506 or DMSO (vehicle) was added to the media as needed. 36 hr post transfection, cells were treated with 1 mM Ionomycin and 1 mM phorbol 12,13 di-butyrate to activate calcineurin and AP-1 (via PKC) respectively. 6 hr after pathway activation, cells were collected, washed in PBS and re-suspended in DMEM media. 80% of the cells were used to measure luciferase activity and renilla using the Dual-Glo assay system (Promega) with three technical replicates. The remaining cells were frozen and stored at −80°C. Cell lysates were prepared in RIPA buffer. 15–20 μg of lysate was analyzed by Western for expression of GFP. GFP signal was normalized to either actin or tubulin. Luciferase activity (normalized to renilla expression) was further normalized to eGFP expression. Data represent at least three experimental replicates.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was supported by NIH/NIGMS grants DP2GM123641 and R01GM107132 to PMF and R01GM119336 to MSC. In addition, PMF is a Chan Zuckerberg Biohub Investigator and acknowledges support from the Beckman Foundation, the Sloan Research Foundation, and PMF and MSC acknowledge the support of a joint Bio-X Interdisciplinary Initiatives Fund seed grant. TK is a Chan Biohub investigator and supported by NIH/NIGMS grants R01GM117189 and R01 GM110089. We thank Prof. Justin Kinney (Cold Spring Harbor Laboratory) for helpful discussions and software used to generate logos; we thank Prof. Dan Herschlag (Stanford) for essential feedback on the manuscript.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Formal analysis, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Investigation, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Software, Formal analysis, Visualization</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Performed all FoldX analysis</p></fn><fn fn-type="con" id="con6"><p>Resources, Synthesized all lanthanide nanophosphors</p></fn><fn fn-type="con" id="con7"><p>Resources, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Expressed and purified tagged calcineurin</p></fn><fn fn-type="con" id="con9"><p>Software, Supervision, Writing—review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Formal analysis, Supervision, Project administration</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Visualization, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.40499.079</object-id><label>Supplementary file 1.</label><caption><title>List of literature affinities and references.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-40499-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><object-id pub-id-type="doi">10.7554/eLife.40499.080</object-id><label>Supplementary file 2.</label><caption><title>Calculated savings and references vs other techniques.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-40499-supp2-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.40499.081</object-id><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-40499-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. In addition, all data generated or analyzed during this study are available in an associated public OSF repository (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17605/OSF.IO/FPVE2">https://doi.org/10.17605/OSF.IO/FPVE2</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Polly</surname><given-names>Morrell Fordyce</given-names></name><name><surname>Huy</surname><given-names>Quoc Nguyen</given-names></name><name><surname>Björn</surname><given-names>Harink</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Quantitative mapping of protein-peptide affinity landscapes using spectrally encoded beads</data-title><source>Open Science Framework</source><pub-id assigning-authority="Open Science Framework" pub-id-type="doi">10.17605/OSF.IO/FPVE2</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldeghi</surname> <given-names>M</given-names></name><name><surname>Gapsys</surname> <given-names>V</given-names></name><name><surname>de Groot</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Accurate estimation of ligand binding affinity changes upon protein mutation</article-title><source>ACS Central Science</source><volume>4</volume><fpage>1708</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.8b00717</pub-id><pub-id pub-id-type="pmid">30648154</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aramburu</surname> <given-names>J</given-names></name><name><surname>Garcia-Cózar</surname> <given-names>F</given-names></name><name><surname>Raghavan</surname> <given-names>A</given-names></name><name><surname>Okamura</surname> <given-names>H</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name><name><surname>Hogan</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT</article-title><source>Molecular Cell</source><volume>1</volume><fpage>627</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80063-5</pub-id><pub-id pub-id-type="pmid">9660947</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aramburu</surname> <given-names>J</given-names></name><name><surname>Yaffe</surname> <given-names>MB</given-names></name><name><surname>López-Rodríguez</surname> <given-names>C</given-names></name><name><surname>Cantley</surname> <given-names>LC</given-names></name><name><surname>Hogan</surname> <given-names>PG</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A</article-title><source>Science</source><volume>285</volume><fpage>2129</fpage><lpage>2133</lpage><pub-id pub-id-type="doi">10.1126/science.285.5436.2129</pub-id><pub-id pub-id-type="pmid">10497131</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atwater</surname> <given-names>J</given-names></name><name><surname>Mattes</surname> <given-names>DS</given-names></name><name><surname>Streit</surname> <given-names>B</given-names></name><name><surname>von Bojničić-Kninski</surname> <given-names>C</given-names></name><name><surname>Loeffler</surname> <given-names>FF</given-names></name><name><surname>Breitling</surname> <given-names>F</given-names></name><name><surname>Fuchs</surname> <given-names>H</given-names></name><name><surname>Hirtz</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Combinatorial synthesis of macromolecular arrays by microchannel cantilever spotting (µCS)</article-title><source>Advanced Materials</source><volume>30</volume><elocation-id>1801632</elocation-id><pub-id pub-id-type="doi">10.1002/adma.201801632</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bagshaw</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2017">2017</year><source>Biomolecular Kinetics: A Step-by-Step Guide</source><publisher-name>CRC Press</publisher-name></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barlow</surname> <given-names>KA</given-names></name><name><surname>Ó Conchúir</surname> <given-names>S</given-names></name><name><surname>Thompson</surname> <given-names>S</given-names></name><name><surname>Suresh</surname> <given-names>P</given-names></name><name><surname>Lucas</surname> <given-names>JE</given-names></name><name><surname>Heinonen</surname> <given-names>M</given-names></name><name><surname>Kortemme</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Flex ddG: rosetta Ensemble-Based estimation of changes in Protein-Protein binding affinity upon mutation</article-title><source>The Journal of Physical Chemistry B</source><volume>122</volume><fpage>5389</fpage><lpage>5399</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.7b11367</pub-id><pub-id pub-id-type="pmid">29401388</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazan</surname> <given-names>J</given-names></name><name><surname>Całkosiński</surname> <given-names>I</given-names></name><name><surname>Gamian</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Phage display—A powerful technique for immunotherapy</article-title><source>Human Vaccines &amp; Immunotherapeutics</source><volume>8</volume><fpage>1817</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.4161/hv.21703</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blikstad</surname> <given-names>C</given-names></name><name><surname>Ivarsson</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>High-throughput methods for identification of protein-protein interactions involving short linear motifs</article-title><source>Cell Communication and Signaling</source><volume>13</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1186/s12964-015-0116-8</pub-id><pub-id pub-id-type="pmid">26297553</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buus</surname> <given-names>S</given-names></name><name><surname>Rockberg</surname> <given-names>J</given-names></name><name><surname>Forsström</surname> <given-names>B</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Uhlen</surname> <given-names>M</given-names></name><name><surname>Schafer-Nielsen</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>High-resolution mapping of linear antibody epitopes using ultrahigh-density peptide microarrays</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>11</volume><fpage>1790</fpage><lpage>1800</lpage><pub-id pub-id-type="doi">10.1074/mcp.M112.020800</pub-id><pub-id pub-id-type="pmid">22984286</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmona</surname> <given-names>SJ</given-names></name><name><surname>Nielsen</surname> <given-names>M</given-names></name><name><surname>Schafer-Nielsen</surname> <given-names>C</given-names></name><name><surname>Mucci</surname> <given-names>J</given-names></name><name><surname>Altcheh</surname> <given-names>J</given-names></name><name><surname>Balouz</surname> <given-names>V</given-names></name><name><surname>Tekiel</surname> <given-names>V</given-names></name><name><surname>Frasch</surname> <given-names>AC</given-names></name><name><surname>Campetella</surname> <given-names>O</given-names></name><name><surname>Buscaglia</surname> <given-names>CA</given-names></name><name><surname>Agüero</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Towards High-throughput immunomics for infectious diseases: use of Next-generation peptide microarrays for rapid discovery and mapping of antigenic determinants</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>14</volume><fpage>1871</fpage><lpage>1884</lpage><pub-id pub-id-type="doi">10.1074/mcp.M114.045906</pub-id><pub-id pub-id-type="pmid">25922409</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="software"><person-group person-group-type="author"><collab>cBioPortal</collab></person-group><year iso-8601-date="2018">2018</year><data-title>cBioPortal for Cancer Genomics Online</data-title><ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/">http://www.cbioportal.org/</ext-link></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Tan</surname> <given-names>PH</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Pei</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>On-bead screening of combinatorial libraries: reduction of nonspecific binding by decreasing surface ligand density</article-title><source>Journal of Combinatorial Chemistry</source><volume>11</volume><fpage>604</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1021/cc9000168</pub-id><pub-id pub-id-type="pmid">19397369</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherf</surname> <given-names>GM</given-names></name><name><surname>Cochran</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Applications of yeast surface display for protein engineering</article-title><source>Methods in Molecular Biology</source><volume>1319</volume><fpage>155</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2748-7_8</pub-id><pub-id pub-id-type="pmid">26060074</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname> <given-names>CW</given-names></name><name><surname>Dong</surname> <given-names>C</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Davis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>c-Jun NH(2)-terminal kinase inhibits targeting of the protein phosphatase calcineurin to NFATc1</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><fpage>5227</fpage><lpage>5234</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.14.5227-5234.2000</pub-id><pub-id pub-id-type="pmid">10866678</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname> <given-names>NE</given-names></name><name><surname>Van Roey</surname> <given-names>K</given-names></name><name><surname>Weatheritt</surname> <given-names>RJ</given-names></name><name><surname>Toedt</surname> <given-names>G</given-names></name><name><surname>Uyar</surname> <given-names>B</given-names></name><name><surname>Altenberg</surname> <given-names>B</given-names></name><name><surname>Budd</surname> <given-names>A</given-names></name><name><surname>Diella</surname> <given-names>F</given-names></name><name><surname>Dinkel</surname> <given-names>H</given-names></name><name><surname>Gibson</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Attributes of short linear motifs</article-title><source>Mol. BioSyst.</source><volume>8</volume><fpage>268</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1039/C1MB05231D</pub-id><pub-id pub-id-type="pmid">21909575</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname> <given-names>NE</given-names></name><name><surname>Seo</surname> <given-names>MH</given-names></name><name><surname>Yadav</surname> <given-names>VK</given-names></name><name><surname>Jeon</surname> <given-names>J</given-names></name><name><surname>Nim</surname> <given-names>S</given-names></name><name><surname>Krystkowiak</surname> <given-names>I</given-names></name><name><surname>Blikstad</surname> <given-names>C</given-names></name><name><surname>Dong</surname> <given-names>D</given-names></name><name><surname>Markova</surname> <given-names>N</given-names></name><name><surname>Kim</surname> <given-names>PM</given-names></name><name><surname>Ivarsson</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Discovery of short linear motif-mediated interactions through phage display of intrinsically disordered regions of the human proteome</article-title><source>The FEBS Journal</source><volume>284</volume><fpage>485</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1111/febs.13995</pub-id><pub-id pub-id-type="pmid">28002650</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeJournette</surname> <given-names>CJ</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Medlen</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Vincent</surname> <given-names>LJ</given-names></name><name><surname>Easley</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Creating biocompatible oil-water interfaces without synthesis: direct interactions between primary amines and carboxylated perfluorocarbon surfactants</article-title><source>Analytical Chemistry</source><volume>85</volume><fpage>10556</fpage><lpage>10564</lpage><pub-id pub-id-type="doi">10.1021/ac4026048</pub-id><pub-id pub-id-type="pmid">24070333</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinkel</surname> <given-names>H</given-names></name><name><surname>Van Roey</surname> <given-names>K</given-names></name><name><surname>Michael</surname> <given-names>S</given-names></name><name><surname>Kumar</surname> <given-names>M</given-names></name><name><surname>Uyar</surname> <given-names>B</given-names></name><name><surname>Altenberg</surname> <given-names>B</given-names></name><name><surname>Milchevskaya</surname> <given-names>V</given-names></name><name><surname>Schneider</surname> <given-names>M</given-names></name><name><surname>Kühn</surname> <given-names>H</given-names></name><name><surname>Behrendt</surname> <given-names>A</given-names></name><name><surname>Dahl</surname> <given-names>SL</given-names></name><name><surname>Damerell</surname> <given-names>V</given-names></name><name><surname>Diebel</surname> <given-names>S</given-names></name><name><surname>Kalman</surname> <given-names>S</given-names></name><name><surname>Klein</surname> <given-names>S</given-names></name><name><surname>Knudsen</surname> <given-names>AC</given-names></name><name><surname>Mäder</surname> <given-names>C</given-names></name><name><surname>Merrill</surname> <given-names>S</given-names></name><name><surname>Staudt</surname> <given-names>A</given-names></name><name><surname>Thiel</surname> <given-names>V</given-names></name><name><surname>Welti</surname> <given-names>L</given-names></name><name><surname>Davey</surname> <given-names>NE</given-names></name><name><surname>Diella</surname> <given-names>F</given-names></name><name><surname>Gibson</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ELM 2016--data update and new functionality of the eukaryotic linear motif resource</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>D294</fpage><lpage>D300</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1291</pub-id><pub-id pub-id-type="pmid">26615199</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogan</surname> <given-names>J</given-names></name><name><surname>Jonasson</surname> <given-names>J</given-names></name><name><surname>Andersson</surname> <given-names>E</given-names></name><name><surname>Jemth</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Binding rate constants reveal distinct features of disordered protein domains</article-title><source>Biochemistry</source><volume>54</volume><fpage>4741</fpage><lpage>4750</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.5b00520</pub-id><pub-id pub-id-type="pmid">26153298</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelmann</surname> <given-names>BW</given-names></name><name><surname>Kim</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Peters</surname> <given-names>B</given-names></name><name><surname>Rock</surname> <given-names>RS</given-names></name><name><surname>Nash</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The development and application of a quantitative peptide microarray based approach to protein interaction domain specificity space</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>3647</fpage><lpage>3662</lpage><pub-id pub-id-type="doi">10.1074/mcp.O114.038695</pub-id><pub-id pub-id-type="pmid">25135669</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippakopoulos</surname> <given-names>P</given-names></name><name><surname>Picaud</surname> <given-names>S</given-names></name><name><surname>Mangos</surname> <given-names>M</given-names></name><name><surname>Keates</surname> <given-names>T</given-names></name><name><surname>Lambert</surname> <given-names>JP</given-names></name><name><surname>Barsyte-Lovejoy</surname> <given-names>D</given-names></name><name><surname>Felletar</surname> <given-names>I</given-names></name><name><surname>Volkmer</surname> <given-names>R</given-names></name><name><surname>Müller</surname> <given-names>S</given-names></name><name><surname>Pawson</surname> <given-names>T</given-names></name><name><surname>Gingras</surname> <given-names>AC</given-names></name><name><surname>Arrowsmith</surname> <given-names>CH</given-names></name><name><surname>Knapp</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Histone recognition and large-scale structural analysis of the human bromodomain family</article-title><source>Cell</source><volume>149</volume><fpage>214</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.013</pub-id><pub-id pub-id-type="pmid">22464331</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fodor</surname> <given-names>SP</given-names></name><name><surname>Read</surname> <given-names>JL</given-names></name><name><surname>Pirrung</surname> <given-names>MC</given-names></name><name><surname>Stryer</surname> <given-names>L</given-names></name><name><surname>Lu</surname> <given-names>AT</given-names></name><name><surname>Solas</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Light-directed, spatially addressable parallel chemical synthesis</article-title><source>Science</source><volume>251</volume><fpage>767</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1126/science.1990438</pub-id><pub-id pub-id-type="pmid">1990438</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsström</surname> <given-names>B</given-names></name><name><surname>Axnäs</surname> <given-names>BB</given-names></name><name><surname>Stengele</surname> <given-names>KP</given-names></name><name><surname>Bühler</surname> <given-names>J</given-names></name><name><surname>Albert</surname> <given-names>TJ</given-names></name><name><surname>Richmond</surname> <given-names>TA</given-names></name><name><surname>Hu</surname> <given-names>FJ</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Hudson</surname> <given-names>EP</given-names></name><name><surname>Rockberg</surname> <given-names>J</given-names></name><name><surname>Uhlen</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Proteome-wide epitope mapping of antibodies using ultra-dense peptide arrays</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>1585</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.1074/mcp.M113.033308</pub-id><pub-id pub-id-type="pmid">24705123</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname> <given-names>R</given-names></name><name><surname>Güler</surname> <given-names>S</given-names></name><name><surname>Krause</surname> <given-names>S</given-names></name><name><surname>Lindenmaier</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Facile and rapid “spot-synthesis” of large numbers of peptides onmembrane sheets</article-title><source>Peptides</source><volume>2</volume><fpage>151</fpage><lpage>152</lpage></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fruman</surname> <given-names>DA</given-names></name><name><surname>Klee</surname> <given-names>CB</given-names></name><name><surname>Bierer</surname> <given-names>BE</given-names></name><name><surname>Burakoff</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A</article-title><source>PNAS</source><volume>89</volume><fpage>3686</fpage><lpage>3690</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.9.3686</pub-id><pub-id pub-id-type="pmid">1373887</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gallicchio</surname> <given-names>E</given-names></name><name><surname>Levy</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2011">2011</year><chapter-title>Recent theoretical and computational advances for modeling protein–ligand binding affinities</chapter-title><source>Advances in Protein Chemistry and Structural Biology</source><volume>85</volume><publisher-name>Elsevier</publisher-name><fpage>27</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-386485-7.00002-8</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gates</surname> <given-names>ZP</given-names></name><name><surname>Vinogradov</surname> <given-names>AA</given-names></name><name><surname>Quartararo</surname> <given-names>AJ</given-names></name><name><surname>Bandyopadhyay</surname> <given-names>A</given-names></name><name><surname>Choo</surname> <given-names>ZN</given-names></name><name><surname>Evans</surname> <given-names>ED</given-names></name><name><surname>Halloran</surname> <given-names>KH</given-names></name><name><surname>Mijalis</surname> <given-names>AJ</given-names></name><name><surname>Mong</surname> <given-names>SK</given-names></name><name><surname>Simon</surname> <given-names>MD</given-names></name><name><surname>Standley</surname> <given-names>EA</given-names></name><name><surname>Styduhar</surname> <given-names>ED</given-names></name><name><surname>Tasker</surname> <given-names>SZ</given-names></name><name><surname>Touti</surname> <given-names>F</given-names></name><name><surname>Weber</surname> <given-names>JM</given-names></name><name><surname>Wilson</surname> <given-names>JL</given-names></name><name><surname>Jamison</surname> <given-names>TF</given-names></name><name><surname>Pentelute</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Xenoprotein engineering via synthetic libraries</article-title><source>PNAS</source><volume>115</volume><fpage>E5298</fpage><lpage>E5306</lpage><pub-id pub-id-type="doi">10.1073/pnas.1722633115</pub-id><pub-id pub-id-type="pmid">29784819</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerver</surname> <given-names>RE</given-names></name><name><surname>Gómez-Sjöberg</surname> <given-names>R</given-names></name><name><surname>Baxter</surname> <given-names>BC</given-names></name><name><surname>Thorn</surname> <given-names>KS</given-names></name><name><surname>Fordyce</surname> <given-names>PM</given-names></name><name><surname>Diaz-Botia</surname> <given-names>CA</given-names></name><name><surname>Helms</surname> <given-names>BA</given-names></name><name><surname>DeRisi</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Programmable microfluidic synthesis of spectrally encoded microspheres</article-title><source>Lab Chip</source><volume>12</volume><fpage>4716</fpage><lpage>4723</lpage><pub-id pub-id-type="doi">10.1039/C2LC40699C</pub-id><pub-id pub-id-type="pmid">23042484</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gfeller</surname> <given-names>D</given-names></name><name><surname>Butty</surname> <given-names>F</given-names></name><name><surname>Wierzbicka</surname> <given-names>M</given-names></name><name><surname>Verschueren</surname> <given-names>E</given-names></name><name><surname>Vanhee</surname> <given-names>P</given-names></name><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Ernst</surname> <given-names>A</given-names></name><name><surname>Dar</surname> <given-names>N</given-names></name><name><surname>Stagljar</surname> <given-names>I</given-names></name><name><surname>Serrano</surname> <given-names>L</given-names></name><name><surname>Sidhu</surname> <given-names>SS</given-names></name><name><surname>Bader</surname> <given-names>GD</given-names></name><name><surname>Kim</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The multiple-specificity landscape of modular peptide recognition domains</article-title><source>Molecular Systems Biology</source><volume>7</volume><elocation-id>484</elocation-id><pub-id pub-id-type="doi">10.1038/msb.2011.18</pub-id><pub-id pub-id-type="pmid">21525870</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gianni</surname> <given-names>S</given-names></name><name><surname>Jemth</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>How fast is Protein-Ligand association?</article-title><source>Trends in Biochemical Sciences</source><volume>42</volume><fpage>847</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2017.08.007</pub-id><pub-id pub-id-type="pmid">28917971</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname> <given-names>TJ</given-names></name><name><surname>Dinkel</surname> <given-names>H</given-names></name><name><surname>Van Roey</surname> <given-names>K</given-names></name><name><surname>Diella</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Experimental detection of short regulatory motifs in eukaryotic proteins: tips for good practice as well as for bad</article-title><source>Cell Communication and Signaling</source><volume>13</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s12964-015-0121-y</pub-id><pub-id pub-id-type="pmid">26581338</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigoriu</surname> <given-names>S</given-names></name><name><surname>Bond</surname> <given-names>R</given-names></name><name><surname>Cossio</surname> <given-names>P</given-names></name><name><surname>Chen</surname> <given-names>JA</given-names></name><name><surname>Ly</surname> <given-names>N</given-names></name><name><surname>Hummer</surname> <given-names>G</given-names></name><name><surname>Page</surname> <given-names>R</given-names></name><name><surname>Cyert</surname> <given-names>MS</given-names></name><name><surname>Peti</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The molecular mechanism of substrate engagement and immunosuppressant inhibition of calcineurin</article-title><source>PLOS Biology</source><volume>11</volume><elocation-id>e1001492</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001492</pub-id><pub-id pub-id-type="pmid">23468591</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerois</surname> <given-names>R</given-names></name><name><surname>Nielsen</surname> <given-names>JE</given-names></name><name><surname>Serrano</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations</article-title><source>Journal of Molecular Biology</source><volume>320</volume><fpage>369</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(02)00442-4</pub-id><pub-id pub-id-type="pmid">12079393</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Harink</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Decoding and analysis software for mrbles (microspheres with ratiometric barcode lanthanide encoding)</data-title><source>Github</source><ext-link ext-link-type="uri" xlink:href="https://github.com/FordyceLab/MRBLEs">https://github.com/FordyceLab/MRBLEs</ext-link></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harink</surname> <given-names>B</given-names></name><name><surname>Nguyen</surname> <given-names>H</given-names></name><name><surname>Thorn</surname> <given-names>K</given-names></name><name><surname>Fordyce</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An open-source software analysis package for microspheres with ratiometric barcode lanthanide encoding (MRBLEs)</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0203725</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0203725</pub-id><pub-id pub-id-type="pmid">30901328</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hein</surname> <given-names>JB</given-names></name><name><surname>Hertz</surname> <given-names>EPT</given-names></name><name><surname>Garvanska</surname> <given-names>DH</given-names></name><name><surname>Kruse</surname> <given-names>T</given-names></name><name><surname>Nilsson</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Distinct kinetics of serine and threonine dephosphorylation are essential for mitosis</article-title><source>Nature Cell Biology</source><volume>19</volume><fpage>1433</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1038/ncb3634</pub-id><pub-id pub-id-type="pmid">29084198</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hintersteiner</surname> <given-names>M</given-names></name><name><surname>Kimmerlin</surname> <given-names>T</given-names></name><name><surname>Kalthoff</surname> <given-names>F</given-names></name><name><surname>Stoeckli</surname> <given-names>M</given-names></name><name><surname>Garavel</surname> <given-names>G</given-names></name><name><surname>Seifert</surname> <given-names>JM</given-names></name><name><surname>Meisner</surname> <given-names>NC</given-names></name><name><surname>Uhl</surname> <given-names>V</given-names></name><name><surname>Buehler</surname> <given-names>C</given-names></name><name><surname>Weidemann</surname> <given-names>T</given-names></name><name><surname>Auer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Single bead labeling method for combining confocal fluorescence on-bead screening and solution validation of tagged one-bead one-compound libraries</article-title><source>Chemistry &amp; Biology</source><volume>16</volume><fpage>724</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2009.06.011</pub-id><pub-id pub-id-type="pmid">19635409</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huttlin</surname> <given-names>EL</given-names></name><name><surname>Ting</surname> <given-names>L</given-names></name><name><surname>Bruckner</surname> <given-names>RJ</given-names></name><name><surname>Gebreab</surname> <given-names>F</given-names></name><name><surname>Gygi</surname> <given-names>MP</given-names></name><name><surname>Szpyt</surname> <given-names>J</given-names></name><name><surname>Tam</surname> <given-names>S</given-names></name><name><surname>Zarraga</surname> <given-names>G</given-names></name><name><surname>Colby</surname> <given-names>G</given-names></name><name><surname>Baltier</surname> <given-names>K</given-names></name><name><surname>Dong</surname> <given-names>R</given-names></name><name><surname>Guarani</surname> <given-names>V</given-names></name><name><surname>Vaites</surname> <given-names>LP</given-names></name><name><surname>Ordureau</surname> <given-names>A</given-names></name><name><surname>Rad</surname> <given-names>R</given-names></name><name><surname>Erickson</surname> <given-names>BK</given-names></name><name><surname>Wühr</surname> <given-names>M</given-names></name><name><surname>Chick</surname> <given-names>J</given-names></name><name><surname>Zhai</surname> <given-names>B</given-names></name><name><surname>Kolippakkam</surname> <given-names>D</given-names></name><name><surname>Mintseris</surname> <given-names>J</given-names></name><name><surname>Obar</surname> <given-names>RA</given-names></name><name><surname>Harris</surname> <given-names>T</given-names></name><name><surname>Artavanis-Tsakonas</surname> <given-names>S</given-names></name><name><surname>Sowa</surname> <given-names>ME</given-names></name><name><surname>De Camilli</surname> <given-names>P</given-names></name><name><surname>Paulo</surname> <given-names>JA</given-names></name><name><surname>Harper</surname> <given-names>JW</given-names></name><name><surname>Gygi</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The BioPlex network: a systematic exploration of the human interactome</article-title><source>Cell</source><volume>162</volume><fpage>425</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.06.043</pub-id><pub-id pub-id-type="pmid">26186194</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huttlin</surname> <given-names>EL</given-names></name><name><surname>Bruckner</surname> <given-names>RJ</given-names></name><name><surname>Paulo</surname> <given-names>JA</given-names></name><name><surname>Cannon</surname> <given-names>JR</given-names></name><name><surname>Ting</surname> <given-names>L</given-names></name><name><surname>Baltier</surname> <given-names>K</given-names></name><name><surname>Colby</surname> <given-names>G</given-names></name><name><surname>Gebreab</surname> <given-names>F</given-names></name><name><surname>Gygi</surname> <given-names>MP</given-names></name><name><surname>Parzen</surname> <given-names>H</given-names></name><name><surname>Szpyt</surname> <given-names>J</given-names></name><name><surname>Tam</surname> <given-names>S</given-names></name><name><surname>Zarraga</surname> <given-names>G</given-names></name><name><surname>Pontano-Vaites</surname> <given-names>L</given-names></name><name><surname>Swarup</surname> <given-names>S</given-names></name><name><surname>White</surname> <given-names>AE</given-names></name><name><surname>Schweppe</surname> <given-names>DK</given-names></name><name><surname>Rad</surname> <given-names>R</given-names></name><name><surname>Erickson</surname> <given-names>BK</given-names></name><name><surname>Obar</surname> <given-names>RA</given-names></name><name><surname>Guruharsha</surname> <given-names>KG</given-names></name><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Artavanis-Tsakonas</surname> <given-names>S</given-names></name><name><surname>Gygi</surname> <given-names>SP</given-names></name><name><surname>Harper</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Architecture of the human interactome defines protein communities and disease networks</article-title><source>Nature</source><volume>545</volume><fpage>505</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1038/nature22366</pub-id><pub-id pub-id-type="pmid">28514442</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivarsson</surname> <given-names>Y</given-names></name><name><surname>Arnold</surname> <given-names>R</given-names></name><name><surname>McLaughlin</surname> <given-names>M</given-names></name><name><surname>Nim</surname> <given-names>S</given-names></name><name><surname>Joshi</surname> <given-names>R</given-names></name><name><surname>Ray</surname> <given-names>D</given-names></name><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Teyra</surname> <given-names>J</given-names></name><name><surname>Pawson</surname> <given-names>T</given-names></name><name><surname>Moffat</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>SS</given-names></name><name><surname>Sidhu</surname> <given-names>SS</given-names></name><name><surname>Kim</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Large-scale interaction profiling of PDZ domains through proteomic peptide-phage display using human and viral phage peptidomes</article-title><source>PNAS</source><volume>111</volume><fpage>2542</fpage><lpage>2547</lpage><pub-id pub-id-type="doi">10.1073/pnas.1312296111</pub-id><pub-id pub-id-type="pmid">24550280</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivarsson</surname> <given-names>Y</given-names></name><name><surname>Jemth</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Affinity and specificity of motif-based protein-protein interactions</article-title><source>Current Opinion in Structural Biology</source><volume>54</volume><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2018.09.009</pub-id><pub-id pub-id-type="pmid">30368054</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname> <given-names>J</given-names></name><name><surname>McCaffrey</surname> <given-names>PG</given-names></name><name><surname>Miner</surname> <given-names>Z</given-names></name><name><surname>Kerppola</surname> <given-names>TK</given-names></name><name><surname>Lambert</surname> <given-names>JN</given-names></name><name><surname>Verdine</surname> <given-names>GL</given-names></name><name><surname>Curran</surname> <given-names>T</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with fos and jun</article-title><source>Nature</source><volume>365</volume><fpage>352</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1038/365352a0</pub-id><pub-id pub-id-type="pmid">8397339</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>L</given-names></name><name><surname>Barclay</surname> <given-names>AN</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>New assay to detect low-affinity interactions and characterization of leukocyte receptors for collagen including leukocyte-associated Ig-like receptor-1 (LAIR-1)</article-title><source>European Journal of Immunology</source><volume>39</volume><fpage>1167</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1002/eji.200839188</pub-id><pub-id pub-id-type="pmid">19283782</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushansky</surname> <given-names>A</given-names></name><name><surname>Allen</surname> <given-names>JE</given-names></name><name><surname>Gordus</surname> <given-names>A</given-names></name><name><surname>Stiffler</surname> <given-names>MA</given-names></name><name><surname>Karp</surname> <given-names>ES</given-names></name><name><surname>Chang</surname> <given-names>BH</given-names></name><name><surname>MacBeath</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Quantifying protein-protein interactions in high throughput using protein domain microarrays</article-title><source>Nature Protocols</source><volume>5</volume><fpage>773</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1038/nprot.2010.36</pub-id><pub-id pub-id-type="pmid">20360771</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kilburg</surname> <given-names>D</given-names></name><name><surname>Gallicchio</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><chapter-title>Recent advances in computational models for the study of protein–peptide interactions</chapter-title><source>Advances in Protein Chemistry and Structural Biology</source><volume>105</volume><publisher-name>Elsevier</publisher-name><fpage>27</fpage><lpage>57</lpage></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krystkowiak</surname> <given-names>I</given-names></name><name><surname>Manguy</surname> <given-names>J</given-names></name><name><surname>Davey</surname> <given-names>NE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>PSSMSearch: a server for modeling, visualization, proteome-wide discovery and annotation of protein motif specificity determinants</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>W235</fpage><lpage>W241</lpage><pub-id pub-id-type="doi">10.1093/nar/gky426</pub-id><pub-id pub-id-type="pmid">29873773</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumaresan</surname> <given-names>PR</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Saunders</surname> <given-names>M</given-names></name><name><surname>Maeda</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Lam</surname> <given-names>KS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Rapid discovery of death ligands with one-bead-two-compound combinatorial library methods</article-title><source>ACS Combinatorial Science</source><volume>13</volume><fpage>259</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1021/co100069t</pub-id><pub-id pub-id-type="pmid">21302937</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname> <given-names>KS</given-names></name><name><surname>Salmon</surname> <given-names>SE</given-names></name><name><surname>Hersh</surname> <given-names>EM</given-names></name><name><surname>Hruby</surname> <given-names>VJ</given-names></name><name><surname>Kazmierski</surname> <given-names>WM</given-names></name><name><surname>Knapp</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>A new type of synthetic peptide library for identifying ligand-binding activity</article-title><source>Nature</source><volume>354</volume><fpage>82</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/354082a0</pub-id><pub-id pub-id-type="pmid">1944576</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Leaver-Fay</surname> <given-names>A</given-names></name><name><surname>Tyka</surname> <given-names>M</given-names></name><name><surname>Lewis</surname> <given-names>SM</given-names></name><name><surname>Lange</surname> <given-names>OF</given-names></name><name><surname>Thompson</surname> <given-names>J</given-names></name><name><surname>Jacak</surname> <given-names>R</given-names></name><name><surname>Kaufman</surname> <given-names>KW</given-names></name><name><surname>Renfrew</surname> <given-names>PD</given-names></name><name><surname>Smith</surname> <given-names>CA</given-names></name><name><surname>Sheffler</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2011">2011</year><chapter-title>Rosetta3: an object-oriented software suite for the simulation and design of macromolecules</chapter-title><source>Methods in Enzymology</source><volume>487</volume><publisher-name>Elsevier</publisher-name><fpage>545</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-381270-4.00019-6</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Bisso</surname> <given-names>PW</given-names></name><name><surname>Srinivas</surname> <given-names>RL</given-names></name><name><surname>Kim</surname> <given-names>JJ</given-names></name><name><surname>Swiston</surname> <given-names>AJ</given-names></name><name><surname>Doyle</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Universal process-inert encoding architecture for polymer microparticles</article-title><source>Nature Materials</source><volume>13</volume><fpage>524</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1038/nmat3938</pub-id><pub-id pub-id-type="pmid">24728464</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name><name><surname>Hogan</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Structural delineation of the calcineurin-NFAT interaction and its parallels to PP1 targeting interactions</article-title><source>Journal of Molecular Biology</source><volume>342</volume><fpage>1659</fpage><lpage>1674</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2004.07.068</pub-id><pub-id pub-id-type="pmid">15364589</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name><name><surname>Harrison</surname> <given-names>SC</given-names></name><name><surname>Hogan</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Structure of calcineurin in complex with PVIVIT peptide: portrait of a low-affinity signalling interaction</article-title><source>Journal of Molecular Biology</source><volume>369</volume><fpage>1296</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.04.032</pub-id><pub-id pub-id-type="pmid">17498738</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Pink</surname> <given-names>MD</given-names></name><name><surname>Murphy</surname> <given-names>JG</given-names></name><name><surname>Stein</surname> <given-names>A</given-names></name><name><surname>Dell'Acqua</surname> <given-names>ML</given-names></name><name><surname>Hogan</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Balanced interactions of calcineurin with AKAP79 regulate Ca2+-calcineurin-NFAT signaling</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>19</volume><fpage>337</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2238</pub-id><pub-id pub-id-type="pmid">22343722</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>R</given-names></name><name><surname>Marik</surname> <given-names>J</given-names></name><name><surname>Lam</surname> <given-names>KS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A novel peptide-based encoding system for &quot;one-bead one-compound&quot; peptidomimetic and small molecule combinatorial libraries</article-title><source>Journal of the American Chemical Society</source><volume>124</volume><fpage>7678</fpage><lpage>7680</lpage><pub-id pub-id-type="doi">10.1021/ja026421t</pub-id><pub-id pub-id-type="pmid">12083920</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Qian</surname> <given-names>Z</given-names></name><name><surname>Xiao</surname> <given-names>Q</given-names></name><name><surname>Pei</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>High-throughput screening of one-bead-one-compound libraries: identification of cyclic peptidyl inhibitors against calcineurin/NFAT interaction</article-title><source>ACS Combinatorial Science</source><volume>13</volume><fpage>537</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1021/co200101w</pub-id><pub-id pub-id-type="pmid">21848276</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meldal</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The one-bead two-compound assay for solid phase screening of combinatorial libraries</article-title><source>Biopolymers</source><volume>66</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1002/bip.10229</pub-id><pub-id pub-id-type="pmid">12325159</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulero</surname> <given-names>MC</given-names></name><name><surname>Aubareda</surname> <given-names>A</given-names></name><name><surname>Orzáez</surname> <given-names>M</given-names></name><name><surname>Messeguer</surname> <given-names>J</given-names></name><name><surname>Serrano-Candelas</surname> <given-names>E</given-names></name><name><surname>Martínez-Hoyer</surname> <given-names>S</given-names></name><name><surname>Messeguer</surname> <given-names>A</given-names></name><name><surname>Pérez-Payá</surname> <given-names>E</given-names></name><name><surname>Pérez-Riba</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) signaling pathway with a regulator of calcineurin-derived peptide without affecting general calcineurin phosphatase activity</article-title><source>Journal of Biological Chemistry</source><volume>284</volume><fpage>9394</fpage><lpage>9401</lpage><pub-id pub-id-type="doi">10.1074/jbc.M805889200</pub-id><pub-id pub-id-type="pmid">19189965</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname> <given-names>MR</given-names></name><name><surname>Sasaki</surname> <given-names>Y</given-names></name><name><surname>Stevanovic</surname> <given-names>I</given-names></name><name><surname>Lamperti</surname> <given-names>ED</given-names></name><name><surname>Ghosh</surname> <given-names>S</given-names></name><name><surname>Sharma</surname> <given-names>S</given-names></name><name><surname>Gelinas</surname> <given-names>C</given-names></name><name><surname>Rossi</surname> <given-names>DJ</given-names></name><name><surname>Pipkin</surname> <given-names>ME</given-names></name><name><surname>Rajewsky</surname> <given-names>K</given-names></name><name><surname>Hogan</surname> <given-names>PG</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Requirement for balanced ca/NFAT signaling in hematopoietic and embryonic development</article-title><source>PNAS</source><volume>106</volume><fpage>7034</fpage><lpage>7039</lpage><pub-id pub-id-type="doi">10.1073/pnas.0813296106</pub-id><pub-id pub-id-type="pmid">19351896</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="patent"><person-group person-group-type="inventor"><name><surname>Nakamura</surname> <given-names>Y</given-names></name><name><surname>Katagiri</surname> <given-names>T</given-names></name><name><surname>Inaki</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent</article-title><source>IFI CLAIMS Patent Services</source><patent country="United States">WO2007013358A2</patent><ext-link ext-link-type="uri" xlink:href="http://www.google.com/patents/WO2007013358A2">http://www.google.com/patents/WO2007013358A2</ext-link></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname> <given-names>T</given-names></name><name><surname>Katagiri</surname> <given-names>T</given-names></name><name><surname>Sato</surname> <given-names>S</given-names></name><name><surname>Kushibiki</surname> <given-names>T</given-names></name><name><surname>Hontani</surname> <given-names>K</given-names></name><name><surname>Tsuchikawa</surname> <given-names>T</given-names></name><name><surname>Hirano</surname> <given-names>S</given-names></name><name><surname>Nakamura</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Overexpression of C16orf74 is involved in aggressive pancreatic cancers</article-title><source>Oncotarget</source><volume>8</volume><fpage>50460</fpage><lpage>50475</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.10912</pub-id><pub-id pub-id-type="pmid">28881575</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neduva</surname> <given-names>V</given-names></name><name><surname>Russell</surname> <given-names>RB</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Peptides mediating interaction networks: new leads at last</article-title><source>Current Opinion in Biotechnology</source><volume>17</volume><fpage>465</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2006.08.002</pub-id><pub-id pub-id-type="pmid">16962311</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>HQ</given-names></name><name><surname>Baxter</surname> <given-names>BC</given-names></name><name><surname>Brower</surname> <given-names>K</given-names></name><name><surname>Diaz-Botia</surname> <given-names>CA</given-names></name><name><surname>DeRisi</surname> <given-names>JL</given-names></name><name><surname>Fordyce</surname> <given-names>PM</given-names></name><name><surname>Thorn</surname> <given-names>KS</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Programmable microfluidic synthesis of over one thousand uniquely identifiable spectral codes</article-title><source>Advanced Optical Materials</source><volume>5</volume><elocation-id>1600548</elocation-id><pub-id pub-id-type="doi">10.1002/adom.201600548</pub-id><pub-id pub-id-type="pmid">28936383</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>HQ</given-names></name><name><surname>Brower</surname> <given-names>K</given-names></name><name><surname>Harink</surname> <given-names>B</given-names></name><name><surname>Baxter</surname> <given-names>B</given-names></name><name><surname>Thorn</surname> <given-names>KS</given-names></name><name><surname>Fordyce</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Peptide library synthesis on spectrally encoded beads for multiplexed protein/peptide bioassays</article-title><conf-name>SPIE 10061, Microfluidics, BioMEMS, and Medical Microsystems XV</conf-name><elocation-id>100610Z</elocation-id><pub-id pub-id-type="doi">10.1117/12.2254908</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollard</surname> <given-names>TD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A guide to simple and informative binding assays</article-title><source>Molecular Biology of the Cell</source><volume>21</volume><fpage>4061</fpage><lpage>4067</lpage><pub-id pub-id-type="doi">10.1091/mbc.e10-08-0683</pub-id><pub-id pub-id-type="pmid">21115850</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname> <given-names>JV</given-names></name><name><surname>Tangsombatvisit</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>G</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Levy</surname> <given-names>D</given-names></name><name><surname>Baechler</surname> <given-names>EC</given-names></name><name><surname>Gozani</surname> <given-names>O</given-names></name><name><surname>Varma</surname> <given-names>M</given-names></name><name><surname>Utz</surname> <given-names>PJ</given-names></name><name><surname>Liu</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions</article-title><source>Nature Medicine</source><volume>18</volume><fpage>1434</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1038/nm.2913</pub-id><pub-id pub-id-type="pmid">22902875</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodríguez</surname> <given-names>A</given-names></name><name><surname>Roy</surname> <given-names>J</given-names></name><name><surname>Martínez-Martínez</surname> <given-names>S</given-names></name><name><surname>López-Maderuelo</surname> <given-names>MD</given-names></name><name><surname>Niño-Moreno</surname> <given-names>P</given-names></name><name><surname>Ortí</surname> <given-names>L</given-names></name><name><surname>Pantoja-Uceda</surname> <given-names>D</given-names></name><name><surname>Pineda-Lucena</surname> <given-names>A</given-names></name><name><surname>Cyert</surname> <given-names>MS</given-names></name><name><surname>Redondo</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A conserved docking surface on calcineurin mediates interaction with substrates and immunosuppressants</article-title><source>Molecular Cell</source><volume>33</volume><fpage>616</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2009.01.030</pub-id><pub-id pub-id-type="pmid">19285944</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolland</surname> <given-names>T</given-names></name><name><surname>Taşan</surname> <given-names>M</given-names></name><name><surname>Charloteaux</surname> <given-names>B</given-names></name><name><surname>Pevzner</surname> <given-names>SJ</given-names></name><name><surname>Zhong</surname> <given-names>Q</given-names></name><name><surname>Sahni</surname> <given-names>N</given-names></name><name><surname>Yi</surname> <given-names>S</given-names></name><name><surname>Lemmens</surname> <given-names>I</given-names></name><name><surname>Fontanillo</surname> <given-names>C</given-names></name><name><surname>Mosca</surname> <given-names>R</given-names></name><name><surname>Kamburov</surname> <given-names>A</given-names></name><name><surname>Ghiassian</surname> <given-names>SD</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Ghamsari</surname> <given-names>L</given-names></name><name><surname>Balcha</surname> <given-names>D</given-names></name><name><surname>Begg</surname> <given-names>BE</given-names></name><name><surname>Braun</surname> <given-names>P</given-names></name><name><surname>Brehme</surname> <given-names>M</given-names></name><name><surname>Broly</surname> <given-names>MP</given-names></name><name><surname>Carvunis</surname> <given-names>AR</given-names></name><name><surname>Convery-Zupan</surname> <given-names>D</given-names></name><name><surname>Corominas</surname> <given-names>R</given-names></name><name><surname>Coulombe-Huntington</surname> <given-names>J</given-names></name><name><surname>Dann</surname> <given-names>E</given-names></name><name><surname>Dreze</surname> <given-names>M</given-names></name><name><surname>Dricot</surname> <given-names>A</given-names></name><name><surname>Fan</surname> <given-names>C</given-names></name><name><surname>Franzosa</surname> <given-names>E</given-names></name><name><surname>Gebreab</surname> <given-names>F</given-names></name><name><surname>Gutierrez</surname> <given-names>BJ</given-names></name><name><surname>Hardy</surname> <given-names>MF</given-names></name><name><surname>Jin</surname> <given-names>M</given-names></name><name><surname>Kang</surname> <given-names>S</given-names></name><name><surname>Kiros</surname> <given-names>R</given-names></name><name><surname>Lin</surname> <given-names>GN</given-names></name><name><surname>Luck</surname> <given-names>K</given-names></name><name><surname>MacWilliams</surname> <given-names>A</given-names></name><name><surname>Menche</surname> <given-names>J</given-names></name><name><surname>Murray</surname> <given-names>RR</given-names></name><name><surname>Palagi</surname> <given-names>A</given-names></name><name><surname>Poulin</surname> <given-names>MM</given-names></name><name><surname>Rambout</surname> <given-names>X</given-names></name><name><surname>Rasla</surname> <given-names>J</given-names></name><name><surname>Reichert</surname> <given-names>P</given-names></name><name><surname>Romero</surname> <given-names>V</given-names></name><name><surname>Ruyssinck</surname> <given-names>E</given-names></name><name><surname>Sahalie</surname> <given-names>JM</given-names></name><name><surname>Scholz</surname> <given-names>A</given-names></name><name><surname>Shah</surname> <given-names>AA</given-names></name><name><surname>Sharma</surname> <given-names>A</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Spirohn</surname> <given-names>K</given-names></name><name><surname>Tam</surname> <given-names>S</given-names></name><name><surname>Tejeda</surname> <given-names>AO</given-names></name><name><surname>Trigg</surname> <given-names>SA</given-names></name><name><surname>Twizere</surname> <given-names>JC</given-names></name><name><surname>Vega</surname> <given-names>K</given-names></name><name><surname>Walsh</surname> <given-names>J</given-names></name><name><surname>Cusick</surname> <given-names>ME</given-names></name><name><surname>Xia</surname> <given-names>Y</given-names></name><name><surname>Barabási</surname> <given-names>AL</given-names></name><name><surname>Iakoucheva</surname> <given-names>LM</given-names></name><name><surname>Aloy</surname> <given-names>P</given-names></name><name><surname>De Las Rivas</surname> <given-names>J</given-names></name><name><surname>Tavernier</surname> <given-names>J</given-names></name><name><surname>Calderwood</surname> <given-names>MA</given-names></name><name><surname>Hill</surname> <given-names>DE</given-names></name><name><surname>Hao</surname> <given-names>T</given-names></name><name><surname>Roth</surname> <given-names>FP</given-names></name><name><surname>Vidal</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A proteome-scale map of the human interactome network</article-title><source>Cell</source><volume>159</volume><fpage>1212</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.10.050</pub-id><pub-id pub-id-type="pmid">25416956</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Hogan</surname> <given-names>PG</given-names></name><name><surname>Cyert</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A conserved docking site modulates substrate affinity for Cal-cineurin, signaling output, and in vivo function</article-title><source>Molecular Cell</source><volume>6</volume><fpage>889</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2007.02.014</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname> <given-names>J</given-names></name><name><surname>Cyert</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cracking the phosphatase code: docking interactions determine substrate specificity</article-title><source>Science Signaling</source><volume>2</volume><elocation-id>re9</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2100re9</pub-id><pub-id pub-id-type="pmid">19996458</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schymkowitz</surname> <given-names>J</given-names></name><name><surname>Borg</surname> <given-names>J</given-names></name><name><surname>Stricher</surname> <given-names>F</given-names></name><name><surname>Nys</surname> <given-names>R</given-names></name><name><surname>Rousseau</surname> <given-names>F</given-names></name><name><surname>Serrano</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The FoldX web server: an online force field</article-title><source>Nucleic Acids Research</source><volume>33</volume><fpage>W382</fpage><lpage>W388</lpage><pub-id pub-id-type="doi">10.1093/nar/gki387</pub-id><pub-id pub-id-type="pmid">15980494</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname> <given-names>ND</given-names></name><name><surname>Mirica</surname> <given-names>KA</given-names></name><name><surname>Soh</surname> <given-names>S</given-names></name><name><surname>Phillips</surname> <given-names>ST</given-names></name><name><surname>Taran</surname> <given-names>O</given-names></name><name><surname>Mace</surname> <given-names>CR</given-names></name><name><surname>Shevkoplyas</surname> <given-names>SS</given-names></name><name><surname>Whitesides</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Measuring binding of protein to gel-bound ligands using magnetic levitation</article-title><source>Journal of the American Chemical Society</source><volume>134</volume><fpage>5637</fpage><lpage>5646</lpage><pub-id pub-id-type="doi">10.1021/ja211788e</pub-id><pub-id pub-id-type="pmid">22364170</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheftic</surname> <given-names>SR</given-names></name><name><surname>Page</surname> <given-names>R</given-names></name><name><surname>Peti</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Investigating the human calcineurin interaction network using the πɸlxvp SLiM</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>38920</elocation-id><pub-id pub-id-type="doi">10.1038/srep38920</pub-id><pub-id pub-id-type="pmid">27974827</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>CA</given-names></name><name><surname>Kortemme</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structure-based prediction of the peptide sequence space recognized by natural and synthetic PDZ domains</article-title><source>Journal of Molecular Biology</source><volume>402</volume><fpage>460</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2010.07.032</pub-id><pub-id pub-id-type="pmid">20654621</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>CA</given-names></name><name><surname>Kortemme</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Predicting the tolerated sequences for proteins and protein interfaces using RosettaBackrub flexible backbone design</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e20451</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0020451</pub-id><pub-id pub-id-type="pmid">21789164</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundell</surname> <given-names>GN</given-names></name><name><surname>Ivarsson</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Interaction analysis through proteomic phage display</article-title><source>BioMed Research International</source><volume>2014</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1155/2014/176172</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Tareen</surname> <given-names>A</given-names></name><name><surname>Kinney</surname> <given-names>JB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Logomaker: beautiful sequence logos in Python</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/635029</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tinti</surname> <given-names>M</given-names></name><name><surname>Kiemer</surname> <given-names>L</given-names></name><name><surname>Costa</surname> <given-names>S</given-names></name><name><surname>Miller</surname> <given-names>ML</given-names></name><name><surname>Sacco</surname> <given-names>F</given-names></name><name><surname>Olsen</surname> <given-names>JV</given-names></name><name><surname>Carducci</surname> <given-names>M</given-names></name><name><surname>Paoluzi</surname> <given-names>S</given-names></name><name><surname>Langone</surname> <given-names>F</given-names></name><name><surname>Workman</surname> <given-names>CT</given-names></name><name><surname>Blom</surname> <given-names>N</given-names></name><name><surname>Machida</surname> <given-names>K</given-names></name><name><surname>Thompson</surname> <given-names>CM</given-names></name><name><surname>Schutkowski</surname> <given-names>M</given-names></name><name><surname>Brunak</surname> <given-names>S</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name><name><surname>Mayer</surname> <given-names>BJ</given-names></name><name><surname>Castagnoli</surname> <given-names>L</given-names></name><name><surname>Cesareni</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The SH2 domain interaction landscape</article-title><source>Cell Reports</source><volume>3</volume><fpage>1293</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.03.001</pub-id><pub-id pub-id-type="pmid">23545499</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tompa</surname> <given-names>P</given-names></name><name><surname>Davey</surname> <given-names>NE</given-names></name><name><surname>Gibson</surname> <given-names>TJ</given-names></name><name><surname>Babu</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A million peptide motifs for the molecular biologist</article-title><source>Molecular Cell</source><volume>55</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.05.032</pub-id><pub-id pub-id-type="pmid">25038412</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonikian</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Sazinsky</surname> <given-names>SL</given-names></name><name><surname>Currell</surname> <given-names>B</given-names></name><name><surname>Yeh</surname> <given-names>JH</given-names></name><name><surname>Reva</surname> <given-names>B</given-names></name><name><surname>Held</surname> <given-names>HA</given-names></name><name><surname>Appleton</surname> <given-names>BA</given-names></name><name><surname>Evangelista</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Xin</surname> <given-names>X</given-names></name><name><surname>Chan</surname> <given-names>AC</given-names></name><name><surname>Seshagiri</surname> <given-names>S</given-names></name><name><surname>Lasky</surname> <given-names>LA</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Boone</surname> <given-names>C</given-names></name><name><surname>Bader</surname> <given-names>GD</given-names></name><name><surname>Sidhu</surname> <given-names>SS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A specificity map for the PDZ domain family</article-title><source>PLOS Biology</source><volume>6</volume><elocation-id>e239</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0060239</pub-id><pub-id pub-id-type="pmid">18828675</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uyar</surname> <given-names>B</given-names></name><name><surname>Weatheritt</surname> <given-names>RJ</given-names></name><name><surname>Dinkel</surname> <given-names>H</given-names></name><name><surname>Davey</surname> <given-names>NE</given-names></name><name><surname>Gibson</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Proteome-wide analysis of human disease mutations in short linear motifs: neglected players in Cancer?</article-title><source>Molecular BioSystems</source><volume>10</volume><fpage>2626</fpage><lpage>2642</lpage><pub-id pub-id-type="doi">10.1039/C4MB00290C</pub-id><pub-id pub-id-type="pmid">25057855</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Roey</surname> <given-names>K</given-names></name><name><surname>Uyar</surname> <given-names>B</given-names></name><name><surname>Weatheritt</surname> <given-names>RJ</given-names></name><name><surname>Dinkel</surname> <given-names>H</given-names></name><name><surname>Seiler</surname> <given-names>M</given-names></name><name><surname>Budd</surname> <given-names>A</given-names></name><name><surname>Gibson</surname> <given-names>TJ</given-names></name><name><surname>Davey</surname> <given-names>NE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Short linear motifs: ubiquitous and functionally diverse protein interaction modules directing cell regulation</article-title><source>Chemical Reviews</source><volume>114</volume><fpage>6733</fpage><lpage>6778</lpage><pub-id pub-id-type="doi">10.1021/cr400585q</pub-id><pub-id pub-id-type="pmid">24926813</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincentelli</surname> <given-names>R</given-names></name><name><surname>Luck</surname> <given-names>K</given-names></name><name><surname>Poirson</surname> <given-names>J</given-names></name><name><surname>Polanowska</surname> <given-names>J</given-names></name><name><surname>Abdat</surname> <given-names>J</given-names></name><name><surname>Blémont</surname> <given-names>M</given-names></name><name><surname>Turchetto</surname> <given-names>J</given-names></name><name><surname>Iv</surname> <given-names>F</given-names></name><name><surname>Ricquier</surname> <given-names>K</given-names></name><name><surname>Straub</surname> <given-names>ML</given-names></name><name><surname>Forster</surname> <given-names>A</given-names></name><name><surname>Cassonnet</surname> <given-names>P</given-names></name><name><surname>Borg</surname> <given-names>JP</given-names></name><name><surname>Jacob</surname> <given-names>Y</given-names></name><name><surname>Masson</surname> <given-names>M</given-names></name><name><surname>Nominé</surname> <given-names>Y</given-names></name><name><surname>Reboul</surname> <given-names>J</given-names></name><name><surname>Wolff</surname> <given-names>N</given-names></name><name><surname>Charbonnier</surname> <given-names>S</given-names></name><name><surname>Travé</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Quantifying domain-ligand affinities and specificities by high-throughput holdup assay</article-title><source>Nature Methods</source><volume>12</volume><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3438</pub-id><pub-id pub-id-type="pmid">26053890</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinogradov</surname> <given-names>AA</given-names></name><name><surname>Gates</surname> <given-names>ZP</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Quartararo</surname> <given-names>AJ</given-names></name><name><surname>Halloran</surname> <given-names>KH</given-names></name><name><surname>Pentelute</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Library Design-Facilitated High-Throughput sequencing of synthetic peptide libraries</article-title><source>ACS Combinatorial Science</source><volume>19</volume><fpage>694</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1021/acscombsci.7b00109</pub-id><pub-id pub-id-type="pmid">28892357</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>HX</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Intrinsic disorder: signaling via highly specific but short-lived association</article-title><source>Trends in Biochemical Sciences</source><volume>37</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2011.11.002</pub-id><pub-id pub-id-type="pmid">22154231</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.40499.085</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Marletta</surname><given-names>Michael A</given-names></name><role>Reviewing Editor</role><aff><institution>University of California, Berkeley</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Gibson</surname><given-names>Toby</given-names> </name><role>Reviewer</role><aff><institution>European Molecular Biology Laboratory</institution><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your work entitled &quot;Quantitative mapping of protein-peptide affinity landscapes using spectrally encoded beads&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: Toby Gibson (Reviewer #2).</p><p>Our decision has been reached after consultation within the editorial board. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in <italic>eLife</italic>. In particular, there was uniform agreement that the issues raised by reviewer 1 are highly unlikely to be addressed in revision.</p><p><italic>Reviewer #1:</italic> </p><p>In this study, the authors present a new technique to measure the affinity of protein-peptide interaction in parallel. They apply their method to the well-known Calcineurin-PxIxIT interaction, obtain more data on this interaction, and use it to identify high-affinity peptides. They validate some of these peptides in a cell-based assay.</p><p>This work is based around the bead-encoded peptide-synthesis and subsequent affinity measurements using the spectral encoding. This all strikes me as technically state-of-the-art and quite elegant. However, from the paper as written, it is a bit difficult to get a true sense of the advantages of the new method over existing ones, and no direct comparison is attempted in the manuscript. For instance, mapping of the affinities of substitutions (as in Figure 4) surely would be possible using SPOT (to a slightly different degree, also using Phage). The shown r<sup>2</sup> of 0.68 is pretty good, but not all that much higher than what has been claimed for SPOT (though a little higher than for phage – see e.g., Ivarsson et al., where, of course, a much higher number of peptides is measured). One should also note that this is for the same protein – incidentally, modern computational methods (such as alchemy-based ones, e.g., TI or CGI) achieve these sort of correlations, and usually perform better than rosetta. As high-quality structures are available, they would be applicable in this case, and may perform similar to the new bead-based method.</p><p>Similar things hold for the high-affinity variants obtained here (Figure 5 or later). While obtaining low-nanomolar binding peptides is really quite good, this domain is (as the authors themselves state) what phage display really is optimized for. While their new method can incorporate non-canonical amino acids, that is similarly true of novel synthetic library methods as what recently came out of the Pentelute lab.</p><p>Finally, while the authors seem to emphasize ability to detect &quot;weak&quot; affinities, I only see convincing data for affinities of up to maybe 50uM, which is all still detectable using techniques such as AP-MS or phage.</p><p>I should note that I do not really want to sound too negative. I see a new technique that brings substantial technical innovation that could be very exciting in this field. However, I find it difficult to ascertain its advantages over the variety of existing methods in the manuscript as presented. I would strongly suggest to include more direct comparisons with existing methods (such as SPOT, ProP-PD, hold-up, etc.) as well a more detailed discussion thereof.</p><p>A few additional points:</p><p>1) The authors state &quot;CN binds PxIxIT peptides with weak affinities.… estimates for known substrates have varied over a wide range.…&quot;. These statements are somewhat contradictory in itself and, in any case, the affinities listed in Figure 2A seem to be all in the single digit uM, which is neither a wide range, nor particularly weak (roughly the expected range for domain-motif interactions).</p><p>2) Given the relatively length of the current paper, it would be good scholarship to discuss existing methods (including the variety of phage-display approaches, SPOT arrays and the recently developed holdup assay) – currently, this all happens in part of a single paragraph, with some of the methods I point out above not even mentioned.</p><p>3) In a similar vein, the citations (or lack thereof) are a bit puzzling. A 12-year old paper (Neduva and Russell) is cited regarding motif-interactions in Y2H/AP-MS, when most of the relevant work was published in the last decade. For Proteomic phage display, only a review paper is cited.</p><p><italic>Reviewer #2:</italic> </p><p>This paper introduces MRBLE-pep, a medium-scale throughput protein-peptide affinity tool and applies it to calcineurin and variants of the PxIxIT docking motif. Using MRBLEs – colour-coded microbeads, each position in the original peptide can be substituted with all other amino acids. Systematic evaluation of binding determinants can then be rapidly determined using small amounts of reagents. Efficient methods for examining SLiM specificities are vey much needed given the abundance of protein:motif interactions in cell regulation and therefore MRBLE could see widespread adoption. Although the PxIxIT motif is well known from several calcineurin substrates, there has been uncertainty regarding the motif specificity determinants as well as the cooperative involvement of the second LxVP docking motif.</p><p>Weight matrices (PSSMs/HMMs) are often used to represent SLiMs in sequence searches but assume that each position in the sequence can be treated independently of the others. Regular expressions are also in widespread use but are overdetermined and insufficiently flexible regarding sequence space. The results here can be used to improve bioinformatic PxIxIT detection in candidate substrate proteins. However, the results also emphasise that positions in the PxIxIT motif are not independent and also that flanking residues affect the binding affinity (which has been seen for a number of other linear motifs too). The data from MRBLE-pep could allow a different computational approach whereby candidate motifs in protein sequences could be compared to and ranked by the total landscape affinity data.</p><p>No substantive concerns were identified.</p><p>[Editors’ note: what now follows is the decision letter after the authors submitted for further consideration.]</p><p>Thank you for resubmitting your work entitled &quot;Quantitative mapping of protein-peptide affinity landscapes using spectrally encoded beads&quot; for further consideration at <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below in the first review below. Normally, we try to avoid second revisions, but we feel reviewer #1's comments should be addressed and we hope you will be able to do this easily and quickly.</p><p><italic>Reviewer #1:</italic> </p><p>Essentially, the revisions by the authors haven't changed my opinions drastically. I still see this is as an innovative technology that will likely be of interest; however, the paper is still hampered by some shortcomings that I think could be improved pretty easily. In a way I find it a bit frustrating that the authors choose to write a full two pages of rebuttal to a simple point (correlations to measured affinity - compare these R<sup>2</sup>s between SPOT and MRBLE-pep) when they could have simply provided two numbers. Also, little of these two pages of rebuttal seems to have made it to the text (or was in there to begin with). Why not provide some kind of comparison of correlation to measured affinity to SPOT in the paper? I'm reasonably certain MRBLE-pep would come out on top.</p><p>Similarly, the authors add calculations using FoldX (that I didn't ask for). Not sure why they include comparisons of FoldX to Rosetta in the main text/figure (these would be of interest in computational papers and indeed have been done a bit, but I doubt the main readership of this paper will be interested). Also, I find it a bit frustrating that while they added a many new figures, the one figure that I think would have added to the paper (again a simple direct comparison of ddGs derived from MRBLE-pep to ones derived from rosetta OR FoldX vs. measured ddGs, i.e. combining the panels of Figure 4—figure supplement 4 into one panel and comparing it to the appropriate one for MRLBLE-pep). It's fine if the authors don't want to do any TI/FEP calculations (again, this isn't a computational paper), though if they do want to make the point that FoldX/Rosetta don't perform well on solvent exposed residues (not surprising), they should also mention that this is something that TI/FEP would, at least in theory, do better at.</p><p>They did add a much more appropriate introduction with discussion of the literature.</p><p><italic>Reviewer #2:</italic> </p><p>The original MRBLE-pep manuscript was rather let down by superficial treatment of other PPI methods and how MARBL-pep compares to them. The resubmitted manuscript is greatly improved in this regard. This is important because SLiM researchers need to be able to understand which methods are suitable for the projects they have in mind. These range from the low throughput &quot;gold standard&quot; ITC up to whole proteome screens of the &quot;disorderome&quot; with phage display to identify novel SLiM candidates. I believe that MARBL-pep will see significant adoption and will help to define many SLiM motif patterns. The data obtained for the chosen target, the Calcineurin-binding PxIxIT motif, will hopefully now be applied in the identification of novel substrates for this medically important phosphatase. I have no further concerns.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.40499.086</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>[Editors’ note: the author responses to the first round of peer review follow.]</p><p>We are writing to follow up on the recent <italic>eLife</italic> review of our manuscript “Quantitative mapping of protein-peptide affinity landscapes using spectrally encoded beads”. We believe that the criticisms are readily addressed and stem largely from the fact that we didn't clearly explain critical differences between our novel assay and current approaches. To frame this discussion, we provide an overview of the reviewers' comments below and attach a detailed response to each of the comments and suggestions.</p><p>Reviewer #2 (Toby Gibson) was very positive, noting that “efficient methods for examining SLiM specificities are very much needed given the abundance of protein:motif interactions in cell regulation”, that “MRBLE could see widespread adoption”, and that “the data from MRBLE-pep could allow a different computational approach whereby candidate motifs in protein sequences could be compared to and ranked by the total landscape affinity data”. We note that Toby Gibson is a world expert in protein-SLiM interactions, and are flattered by his positive reception to the work.</p><p>Reviewer #1 stated that the work was “technically state-of-the-art and quite elegant” and that they “see a new technique that brings substantial technical innovation that could be very exciting in this field”. However, they state that they found it “difficult to ascertain its advantages over the variety of existing methods in the manuscript as presented” and would “strongly suggest to include more direct comparisons with existing methods (such as SPOT, ProP-PD, hold-up, etc)”. This helpful suggestion is easily addressed in the text of the manuscript. To briefly summarize advantages of MRBLE-pep:</p><p>1) MRBLEs have been engineered to have very slow on- and off-rates (half-lives of ~ 5 hours), allowing equilibrium measurement of even weak and transient SLiM interactions to yield quantitative thermodynamic constants (K_D and ΔΔG). This is simply not possible with SPOT arrays or ProP-PD, as off-rates for domain-SLiM interactions are on the order of seconds, much shorter than typical washing steps such that interactions with fast off-rates are preferentially lost.</p><p>2) MRBLE-pep incorporates in-line quality control to provide critical negative information about residues that ablate or reduce binding that is not available via SPOT or ProP-PD.</p><p>3) MRBLE-pep allows direct assessment of the effects of post-translational modifications (not possible with ProP-PD).</p><p>4) MRBLE-pep requires significantly less material than current low-throughput quantitative techniques (~60000x less protein and ~6000x less peptide than micro/nano ITC).</p><p>Finally, we note that we apply this new technology towards studying a system of great biological interest and reveal new information about determinants of specificity. As Toby Gibson notes, “the results here could be used to improve bioinformatic PxIxIT in candidate substrate proteins” and “emphasize that positions in the PxIxIT motif are not independent and also that flanking residues affect the binding affinity”.</p><p>Reviewer #1:</p><disp-quote content-type="editor-comment"><p>In this study, the authors present a new technique to measure the affinity of protein-peptide interaction in parallel. They apply their method to the well-known Calcineurin-PxIxIT interaction, obtain more data on this interaction, and use it to identify high-affinity peptides. They validate some of these peptides in a cell-based assay.</p><p>This work is based around the bead-encoded peptide-synthesis and subsequent affinity measurements using the spectral encoding. This all strikes me as technically state-of-the-art and quite elegant.</p></disp-quote><p>We appreciate the reviewer’s kind opinion that the method is “technically state-of-the-art and quite elegant”!</p><disp-quote content-type="editor-comment"><p>However, from the paper as written, it is a bit difficult to get a true sense of the advantages of the new method over existing ones, and no direct comparison is attempted in the manuscript. For instance, mapping of the affinities of substitutions (as in Figure 4) surely would be possible using SPOT (to a slightly different degree, also using Phage). The shown r<sup>2</sup> of 0.68 is pretty good, but not all that much higher than what has been claimed for SPOT (though a little higher than for phage – see e.g., Ivarsson et al., where, of course, a much higher number of peptides is measured).</p></disp-quote><p>The reviewer makes an excellent point. We did not clearly explain the advantages and disadvantages of MRBLE-pep relative to current techniques, and we also did not emphasize why quantitative measurements of interaction affinities are so important! We appreciate the helpful suggestions for how to improve the manuscript. In response, we have extensively revised the text in the Introduction and Discussion to include several paragraphs comparing and contrasting MRBLE-pep to current technologies.</p><p>To ensure that we clearly communicate these points, we also discuss the advantages and disadvantages of these approaches here, where we are not constrained by length.</p><p>Array-based methods:</p><p>Array-based methods provide the ability to probe for interactions between a protein of interest and 10s<sup>-1</sup>00s (SPOT arrays) or up to millions (ultra-high density arrays) peptides in a single experiment (Frank et al., 1990; Atwater et al., 2018; Buus et al., 2012; Forsstrom et al., 2014; Price et al., 2012; Carmona et al., 2015). In most cases, peptides are synthesized in situ via chemical synthesis approaches, making it possible to profile interactions between proteins and peptides containing unnatural amino acids or post-translational modifications at known positions. However, array-based methods cannot return quantitative interaction affinities (dissociation constants (K<sub>D</sub>s) or relative affinities (ΔΔGs)) because the measurements do not take place at thermodynamic equilibrium. Following incubation of proteins of interest with a peptide of interest, arrays must be washed extensively prior to imaging to quantify bound material; when a fluorescently-labeled antibody is used to detect bound protein, two incubations and two washing steps are required. In either case, the long washing times (minutes to hours) relative to the interaction dissociation rates (seconds) (Zhou et al., 2012; Dogan et al., 2015; and discussion in Ivarsson et al., 2019) mean that only the most persistent interactions are retained and interactions with faster off-rates are preferentially lost. Multiple comparisons between bound protein intensities and measured affinities for array-based experiments have established that while intensities typically correlate well with affinities for high-affinity interactions, arrays fail to recover weaker interactions. Finally, array-based methods are associated with high numbers of false positive and false negative measurements because it is difficult to evaluate the yield and purity of peptides present in each spot (Blikstad et al., 2015).</p><p>MRBLE-pep offers the following advantages relative to array-based methods:</p><p>1) Equilibrium measurements to yield affinities. As shown in Figure 2—figure supplements 1 and 2, we have deliberately engineered MRBLE polymer beads to have extremely slow on- and off-rates. This property makes it possible to remove unbound material and image to quantify bound protein with the washing steps taking place over a period of time that is much smaller than the half-life of the reactions, thereby approximating equilibrium and allowing direct measurement of interaction affinities.</p><p>2) In-line quality control for yield negative binding information. The use of different chemical linkers in the MRBLE core and periphery make it possible to cleave synthesized peptides from the MRBLE core only and directly assess their quality via MALDI-TOF mass spectrometry while preserving peptides presented at the periphery for binding measurements. If quality control reveals issues with synthesis, particular MRBLE-peptide combinations can simply be re-synthesized, re-tested, and added to the pool.</p><p>3) Statistical replicates. Each pooled measurement assesses binding of protein to ~ 30 beads containing the same embedded code and displayed sequence, allowing robust discrimination of even subtle differences in binding between sequences.</p><p>Display-based methods: Display-based methods have the advantage of profiling interactions between SLiM-binding proteins and large numbers (up to 10<sup>10</sup>) of candidate SLiMs. While approaches using combinatorial peptide libraries were biased towards identifying hydrophobic substrates, Ylva Ivarsson’s lab has pioneered new approaches for profiling interactions between SLiM-binding proteins and peptides tiled across intrinsically disordered regions of the proteome (Pro- PD) that remove this bias, as well as a newer approach that profiles peptides containing either serines and threonines or phosphomimetic residues at the same position to examine phosphorylation-dependent binding specificities.</p><p>However, a primary disadvantage of display-based methods is that they cannot return thermodynamic interaction affinities. Display-based techniques require multiple rounds of selection and washing, and as a result, take place out of equilibrium and provide only semi-quantitative estimates of binding strength biased towards SLiMs with the slowest dissociation rates. While computational approaches for extracting binding affinities from all rounds of selection have recently been developed for and applied towards high-throughput measurements of transcription factor-DNA affinities via SELEX approaches (e.g. No Read Left Behind, Rastogi et al., PNAS 2018), current Pro-PD and ProP-PD experiments typically consider NGS reads from a single round of enrichment (e.g. the fourth round of selection) only. In addition, display-based techniques cannot return information about the effects of post-translational modifications. While ProP-PD incorporates phosphomimetic residues in place of native serines and threonines to attempt to probe the effects of phosphorylation, we demonstrate here that phosphomimetic residues do not always fully mimic the effects of phosphorylation (here, phosphorylation at position 9 increases affinities 50-fold while phosphomimetic residues have essentially no effect). Finally, display-based techniques return a high number of false positives and false negatives and must therefore be validated via an alternate approach such as isothermal calorimetry. Finally, all selection-based methods, including Pro-PD, return only positive information (i.e. identify motifs that interact with the domain in question), but do not directly test if a particular sequence binds. Therefore, critical information about residues that prevent binding is not identified.</p><p>In fact, MRBLE-pep is a perfect complement to Pro-PD. After identifying selected sequences via Pro-PD, MRBLE-pep could be used to validate binding to identified peptides, determine binding affinities and test effects of amino substitutions on affinity for comprehensive motif characterization. We have modified the manuscript to make this point more explicit, and appreciate the reviewer’s suggestion.</p><p>Other methods:</p><p>Y2H and AP-MS: A recent large-scale yeast-two-hybrid (Y2H) screen identified 14000 potential binary protein-protein interactions to reveal the human interactome network, representing a milestone in knowledge of this network (Rolland et al., 2014). Over the following years, other groups have expanded the knowledge of this network via AP-MS assays to detect interactions (Huttlin et al., 2015; Huttlin et al., 2017), revealing ~23,000 and 56,000 interactions, respectively. However, interactions between SLiMs and SLiM-binding proteins remain particularly underrepresented (Van Roey et al., 2014; Davey et al., 2017). Underrepresentation in AP-MS is likely due to the low affinities and fast dissociation rates for SLiM-mediated interactions and the need for washing steps in this technique. In addition, neither Y2H or AP-MS methods claim to return quantitative interaction affinities. Moreover, AP-MS reports only on the presence of an interaction between 2 protein components, without information about whether this interaction is binary or what protein fragment/motif is responsible.</p><p>Hold-up assay: The hold-up assay represents the most direct competitor to the work presented here. This method was first described in an elegant and thorough Nature Methods paper from 2015 by Vincentelli and colleagues in which they profiled interactions between 210 PDZ-peptide pairs with known affinities and then mapped the specificity landscape between 2 viral PDZ-binding motifs from human papillomavirus E6 oncoproteins and 209 PDZ domains. While this assay detects complexes binding at equilibrium (in contrast to other high-throughput methods mentioned above), in its standard form, the assay returns only ranked lists of likely interaction strengths (not actual affinities). Deriving quantitative affinity information for complexes with K<sub>D</sub> &gt; 8 µM requires repetition of the assay at higher protein concentrations in order to ensure that available soluble protein is not significantly depleted within the unbound fraction. As a result, the material requirements for the hold-up assay significantly exceed those for the assay presented here. Finally, we note that the hold- up assay has never been cited in subsequent experimental work, suggesting that there are significant technical barriers to widespread adoption.</p><p>Because most high-throughput technologies take place out of thermodynamic equilibrium and therefore cannot measure quantitative interaction affinities (equilibrium constants), the vast majority of SLiMs have been characterized by low- throughput experimentation (see Davey et al., 2017; Dinkel et al., 2016; Toniian et al., 2008). Rather than viewing high-throughput screening methods as competing technologies for MRBLE-pep, we believe that the two approaches are highly complementary. The large sequence spaces accessible to display-based methods make it possible to scan large sequence spaces for candidate interaction motifs. After such a scan, MRBLE-pep can be used to: (1) quickly and efficiently scan through thousands of potential SLiMs to validate true hits, (2) directly measure SLiM interaction affinities, and then (3) systematically perturb identified motifs to map the surrounding binding affinity landscape, assess binding specificity, and determine a position specific affinity matrix that can be used to more accurately predict candidate downstream targets across the proteome. MRBLE-pep has the potential to streamline tedious downstream validation and affinity measurement process relative to traditional quantitative biotechniques such as fluorescence polarization, surface plasmon resonance, and isothermal calorimetry. We have amended the Discussion to more clearly emphasize that we view MRBLE-pep as a method that is complementary to (rather than competitive with) high-throughput discovery techniques, and hope that this addresses this reviewer’s concerns.</p><disp-quote content-type="editor-comment"><p>One should also note that this is for the same protein – incidentally, modern computational methods (such as alchemy-based ones, e.g., TI or CGI) achieve these sort of correlations, and usually perform better than rosetta. As high-quality structures are available, they would be applicable in this case, and may perform similar to the new bead-based method.</p></disp-quote><p>We agree with the reviewer that including other computational methods will likely improve the ability to accurately predict the energetic effects of SLiM mutations. In particular, the reviewer suggests that alchemical free energy calculations may improve these predictions. However, a previous paper (Aldeghi et al., 2018) directly compared performance between these calculations and Rosetta flex_ddG and concluded:</p><p>“We show that both the free energy calculations and Rosetta are able to quantitatively predict changes in ligand binding affinity upon protein mutations, yet the best predictions are the result of combining the estimates of both methods.”</p><p>They also note the difference in computational cost:</p><p>“It is important to put the performances of the calculations in the context of their computational cost. With the free energy calculations, each ΔΔG estimate took between 2 and 5 days on a node with 20 CPU threads and 1 GPU (Intel Xeon E5-2630 v4; GTX 1080 Ti), depending on the size of the system (from ~30000 to ~100000 atoms). With the flex_ddG protocol, each ΔΔG estimate took up to a day on a single CPU core.”</p><p>To address the reviewer’s suggestion, we worked with Naomi Latorroca from Ron Dror’s lab at Stanford to use the FoldX server to predict the likely change in binding energy upon mutating different residues within PxIxIT peptides on calcineurin- PxIxIT binding affinities (see Figure 4 and associated supplementary figures and data sets). In many cases, the FoldX predictions outperformed those of the Rosetta flex_ddG protocol when assessing the ability to classify predicted substitutions as either stabilizing (ΔΔG &lt; 0) or destabilizing (ΔΔG &gt; 0), and we think that the manuscript has been improved as a result. We note, however, that the prediction accuracy remains somewhat low, consistent with the prevailing sentiment that predicting mutational effects for protein-peptide interactions remains a difficult problem due to the large number of possible conformations of the peptide when free in solution. MRBLE-pep therefore provides a unique opportunity to iterate quickly between computational predictions and experimental measurements, as high-throughput peptide synthesizers allow synthesis of up to 576 peptides on MRBLEs in parallel in about a week and downstream binding assays require only a few additional days. The inclusion of this analysis has substantially improved the paper and we appreciate the reviewer’s suggestion!</p><disp-quote content-type="editor-comment"><p>Similar things hold for the high-affinity variants obtained here (Figure 5 or later). While obtaining low-nanomolar binding peptides is really quite good, this domain is (as the authors themselves state) what phage display really is optimized for.</p></disp-quote><p>We appreciate the reviewer’s point that identifying super-binders is easily accomplished via a variety of other methods, including phage display, that allow searching of extremely large combinatorial libraries (up to 1010). However, the current approach demonstrated the ability to identify peptides with affinities 2 orders of magnitude stronger than those previously identified via phage display using only 400 measurements. This brings up an interesting question: what is the most efficient way to scan a potential sequence space? For peptides that bind as linear motifs, the results presented here suggest that systematically testing a single mutation at each position and then combining those results may provide an alternative method to obtain the same results via a much smaller number of experimental measurements.</p><disp-quote content-type="editor-comment"><p>While their new method can incorporate non-canonical amino acids, that is similarly true of novel synthetic library methods as what recently came out of the Pentelute lab.</p></disp-quote><p>We appreciate the discussion of the exciting new technologies that have emerged from the Pentelute lab. We regret failing to cite these in our initial submission and have amended this by including several citations in the current text. Again, however, we emphasize that these technologies are screening technologies that, while able to test a wide variety of potential interactions (including a wide variety of unnatural and modified amino acids), do not return quantitative interaction affinities. As with phage display, we view the current MRBLE-pep technology as complementary to, rather than competitive with, these screening technologies. We have amended the text to include references to 2 recent relevant publications from the Pentelute lab.</p><disp-quote content-type="editor-comment"><p>Finally, while the authors seem to emphasize ability to detect &quot;weak&quot; affinities, I only see convincing data for affinities of up to maybe 50uM, which is all still detectable using techniques such as AP-MS or phage.</p></disp-quote><p>We respectfully disagree with the reviewer’s suggestion that affinities of up to 50 µM are detectable using AP-MS, as prior analyses have demonstrated that low-affinity SLiM-mediated interactions are significantly underrepresented within these datasets, as described above. However, even if these interactions were not underrepresented within AP-MS datasets, there would still be a need to directly and quantitatively measure the interaction affinities to predict biological responses and downstream outputs, as well as to acquire <italic>in vitro</italic> data to distinguish between direct and indirect binding interactions. For this reason, we again suggest that MRBLE-pep may represent an ideal companion technology to quantify affinities for candidate AP-MS interactions to decode cellular signaling interaction networks and for use in whole-cell modeling efforts.</p><disp-quote content-type="editor-comment"><p>I should note that I do not really want to sound too negative. I see a new technique that brings substantial technical innovation that could be very exciting in this field. However, I find it difficult to ascertain its advantages over the variety of existing methods in the manuscript as presented. I would strongly suggest to include more direct comparisons with existing methods (such as SPOT, ProP-PD, hold-up, etc.) as well a more detailed discussion thereof.</p></disp-quote><p>We appreciate the reviewer’s encouraging comment that the review is not meant to sound too negative, as well as the sentiment that this is “a new technique that brings substantial technical innovation that could be very exciting in this field”! We believe that the reviewer’s suggestions to include more direct comparisons between MRBLE-pep and these existing techniques as well as to explore additional computational methods for predicting mutational effects on protein-peptide affinities have strengthened the paper considerably. We have significantly revised the Introduction in response to these helpful suggestions.</p><disp-quote content-type="editor-comment"><p>A few additional points:</p><p>1) The authors state &quot;CN binds PxIxIT peptides with weak affinities.… estimates for known substrates have varied over a wide range.…&quot;. These statements are somewhat contradictory in itself and, in any case, the affinities listed in Figure 2A seem to be all in the single digit uM, which is neither a wide range, nor particularly weak (roughly the expected range for domain-motif interactions).</p></disp-quote><p>We agree with the reviewer that single digit µM Kd values are typical for SLiM-mediated binding interactions. However, SLiM-mediated binding interactions are typically referred to as moderate-to-weak affinity and transient (for example, please see Davey et al., 2012). To address this suggestion, we have amended the text to read “CN binds PxIxIT peptides with moderate-to-weak affinities…”. When we suggest that estimates for known substrates have varied over a wide range, we mean to say that published estimates for the same specific interaction between CN and a particular SLiM have varied over a wide range. To clarify this, we have amended the text to read: “… prior literature affinity estimates for a given substrate have varied over 50-fold.”</p><disp-quote content-type="editor-comment"><p>2) Given the relatively length of the current paper, it would be good scholarship to discuss existing methods (including the variety of phage-display approaches, SPOT arrays and the recently developed holdup assay) – currently, this all happens in part of a single paragraph, with some of the methods I point out above not even mentioned.</p></disp-quote><p>We appreciate the suggestion and have revised the Introduction extensively to include a more detailed discussion of other methods, as detailed above. We sincerely regret the oversight in the initial submission.</p><disp-quote content-type="editor-comment"><p>3) In a similar vein, the citations (or lack thereof) are a bit puzzling. A 12-year old paper (Neduva and Russell) is cited regarding motif-interactions in Y2H/AP-MS, when most of the relevant work was published in the last decade. For Proteomic phage display, only a review paper is cited.</p></disp-quote><p>The reviewer makes an excellent point. In re-reading the paper, it’s clear that we were overly focused on presenting the data and did an embarrassingly poor job of referencing much of the recent literature. We again regret this oversight and have extensively rewritten the Introduction and amended the paper to include a much more comprehensive discussion of recently published work. This is another case where we feel that the reviewer’s suggestions have significantly improved the paper by making comparisons to other methods more clear!</p><p>Reviewer #2:</p><disp-quote content-type="editor-comment"><p>[…] Weight matrices (PSSMs/HMMs) are often used to represent SLiMs in sequence searches but assume that each position in the sequence can be treated independently of the others. Regular expressions are also in widespread use but are overdetermined and insufficiently flexible regarding sequence space. The results here can be used to improve bioinformatic PxIxIT detection in candidate substrate proteins. However, the results also emphasise that positions in the PxIxIT motif are not independent and also that flanking residues affect the binding affinity (which has been seen for a number of other linear motifs too). The data from MRBLE-pep could allow a different computational approach whereby candidate motifs in protein sequences could be compared to and ranked by the total landscape affinity data.</p><p>No substantive concerns were identified.</p></disp-quote><p>We appreciate the reviewer’s kind words and positive assessment of the work! We particularly appreciate that the reviewer correctly noted the ability of MRBLE-pep to provide quantitative information about interaction epistasis. We have added an additional sentence to the manuscript to emphasize this point.</p><p>[Editors’ note: the author responses to the re-review follow.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below in the first review below. Normally, we try to avoid second revisions, but we feel reviewer #1's comments should be addressed and we hope you will be able to do this easily and quickly.</p></disp-quote><p>Reviewer #1:</p><disp-quote content-type="editor-comment"><p>Essentially, the revisions by the authors haven't changed my opinions drastically. I still see this is as an innovative technology that will likely be of interest; however, the paper is still hampered by some shortcomings that I think could be improved pretty easily. In a way I find it a bit frustrating that the authors choose to write a full two pages of rebuttal to a simple point (correlations to measured affinity – compare these R<sup>2</sup>s between SPOT and MRBLE-pep) when they could have simply provided two numbers. Also, little of these two pages of rebuttal seems to have made it to the text (or was in there to begin with). Why not provide some kind of comparison of correlation to measured affinity to SPOT in the paper? I'm reasonably certain MRBLE-pep would come out on top.</p></disp-quote><p>The reviewer makes an excellent suggestion, and we fully agree that this would be a very interesting and worthwhile comparison. Unfortunately, this is simply not possible with current published data, largely due to the technical challenges associated with measuring quantitative binding affinities. Prior literature includes estimates of measured affinities for only a handful of calcineurin-PxIxIT interactions, all 8 of which we also measured via MRBLE-pep (Figure 2C). The strong agreement between MRBLE-pep affinities and these 8 prior measurements is shown in Figure 2D (r2 = 0.68), with only NFATc2 (PRIEIT) showing significant deviation. To clarify that this data set represents all known prior published affinities, we have modified a sentence in the “MRBLE-pep yield quantitative measurements of calcineurin binding affinities” to read: “These 10 peptides (the “Triplicate low” dataset) represent all calcineurinbinding SLiMs for which affinities have been measured, including the known NFATc1, NFATc2, AKAP79, and RCAN1 natural CN-interacting PxIxIT binding site (citations), a set of 5 PVIVIT peptide mutants previously characterized via competitive fluorescence polarization assays (citations), and a scrambled negative control sequence.”</p><p>These peptides have not been measured via SPOT arrays, preventing the desired comparison. The only published paper using arrays to quantify binding to calcineurin assessed binding of tiled calcineurin fragments to a single PxIxIT motif (the NFATc2 SLiM SGPSPRIEITPSH) and was unable to detect any binding between calcineurin fragments and the known PVIVIT substrate (Erdmann et al., ChemBioChem 2018). To fully address the reviewer’s request without relying on previously published literature, we attempted to perform ITC for a series of calcineurin-peptide interactions for approximately 3 months but were ultimately unsuccessful.</p><disp-quote content-type="editor-comment"><p>Similarly, the authors add calculations using FoldX (that I didn't ask for). Not sure why they include comparisons of FoldX to Rosetta in the main text/figure (these would be of interest in computational papers and indeed have been done a bit, but I doubt the main readership of this paper will be interested). Also, I find it a bit frustrating that while they added a many new figures, the one figure that I think would have added to the paper (again a simple direct comparison of ddGs derived from MRBLE-pep to ones derived from rosetta OR FoldX vs. measured ddGs, i.e. combining the panels of Figure 4—figure supplement 4 into one panel and comparing it to the appropriate one for MRLBLE-pep).</p></disp-quote><p>Figure 4—figure supplement 5 and Figure 4—figure supplement 6 compare MRBLE-pep measurements to the predictions of FoldX and the Rosetta flex_ddG protocol, respectively. Of the prior published measurements of calcineurin- PxIxIT affinities, only a single study considered how systematic substitutions within the PVIVIT site affect measured affinities by performing fluorescence polarization measurements in the presence of competing unlabeled peptides to estimate affinities (Li and Hogan, 2007). The FoldX and Rosetta computational analyses estimate effects on affinity for all possible single-site substitutions within the PVIVITGPH site, and therefore require orthogonal measurements of single-site substitutions for comparison. The Li and Hogan experiments measure relative affinities for only the wildtype PVIVIT peptide and 2 examples of single-site substitutions from the PVIVIT motif (PVIVVT and PVIVIN); the other measurement includes 2 amino acid mutations (PVIAVT).</p><p>The only possible comparison between MRBLE-pep, FoldX, and Rosetta and prior published results therefore assesses their performance on 2 WT-like peptides (PVIVIT and PVIVVT) and one weak affinity variant (PVIVIN), resulting in a 3-point comparison for which 2 points are experimentally identical. The MRBLE-pep measurements alone (and not the FoldX and Rosetta computational predictions) correctly recapitulate that: (1) PVIVIT and PVIVVT have the same affinities) and (2) the PVIVIN substitution substantially reduces binding.</p><p>In response to the reviewer suggestion, we have included this figure as Figure 4—figure supplement 7, and also added the following to the text: “Comparisons of MRBLE-pep measurements and Rosetta and FoldX predictions of the energetic effects of single site substitutions with orthogonal measurements are complicated by a lack of previously published affinity data. However, a direct comparison between MRBLE-pep measurements and computational predictions for 2 single-site substitutions in the PVIVIT motif reveal that only MRBLE-pep correctly discerns that a PVIVVT substitution has little effect while a PVIVIN substitution reduces binding.”</p><disp-quote content-type="editor-comment"><p>It's fine if the authors don't want to do any TI/FEP calculations (again, this isn't a computational paper), though if they do want to make the point that FoldX/Rosetta don't perform well on solvent exposed residues (not surprising), they should also mention that this is something that TI/FEP would, at least in theory, do better at.</p></disp-quote><p>We thank the reviewer for this suggestion and have added the following sentence to the section “Comparing experimental measurements with results from structure-based computational predictions”: “Thermodynamic Integration and Free Energy Perturbation (TI/FEP) methods would likely enhance the ability to predict effects of mutating solvent-exposed residues, but are significantly more computationally expensive (Kilburg and Gallichio, 2016; Gallichio and Levy, 2011).”</p><disp-quote content-type="editor-comment"><p>They did add a much more appropriate Introduction with Discussion of the literature.</p></disp-quote><p>We thank the reviewer for this suggestion, agree that the discussion of the literature is much improved, and apologize for the initial oversight.</p></body></sub-article></article>